Compound · clinical trials

Paclitaxel clinical trials

Also listed in trial records as Onxol, Anzatax, Asotax, Bristaxol, Praxel, Nov-Onxol, Navaplus, Paclitax, Paclitaxin, Paxene, Onxal

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 423 trials in our China, USA, Spain, South Korea, France, Canada, Italy, Japan, Germany, UK, Taiwan, Poland, Australia, Mexico, Israel, Brazil, Belgium, Turkey, Netherlands, Czechia, Austria, Denmark, India, Singapore, Sweden, Switzerland, Norway, Portugal, Ireland and Egypt registers that name Paclitaxel as an intervention. Synced 10 Nov 2026

423Current trials

222Recruiting now

204Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 10 Nov 2026 · Editorial standards

At a glance

Paclitaxel is named as an intervention in 423 current clinical trials in our China, USA, Spain, South Korea, France, Canada, Italy, Japan, Germany, UK, Taiwan, Poland, Australia, Mexico, Israel, Brazil, Belgium, Turkey, Netherlands, Czechia, Austria, Denmark, India, Singapore, Sweden, Switzerland, Norway, Portugal, Ireland and Egypt registers. 222 are recruiting patients now. The most common phase is Phase 3. The sponsor with the most trials is Merck Sharp & Dohme LLC (30). The most-studied condition is Breast Cancer. The EU clinical trials register (CTIS) separately lists 26 authorised or ongoing trials, 2 with a site in Ireland.

Where Paclitaxel is approved

All regulators →

Of the three regulators tracked here, the first to approve Paclitaxel was the US, on 29 Dec 1992. It is approved in 3 of the 3 regulators tracked here.

USUnited States (FDA)

29 Dec 1992

Taxol

NDA020262 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

19 Jul 1999

Paxene

EMA product page

First centralised authorisation

CACanada (Health Canada)

2 Jul 1997

Paclitaxel Injection

Notice of Compliance 4006

First new-drug NOC

6 EU orphan designations, most recently for treatment of gastric cancer (19 Feb 2024, positive)
1 EU safety letter (DHPC), latest: medicine shortage for Pazenir, 24 Jan 2023

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

Paclitaxel patents and exclusivity

Expiry tracker →

Protections still running for marketed products containing Paclitaxel, as listed by the regulators. Expired patents and exclusivities, and discontinued products, are not shown.

US FDA Orange Book Abraxane, Paclitaxel

4 listed patents; the last listed expires 12 Jul 2034 (US 9511046, including a 6-month paediatric extension).

See the Orange Book listing for NDA 021660

Patents and exclusivities above are pooled across 3 applications for this substance.

Reproduced from the FDA Orange Book and Purple Book (checked 8 Nov 2026) and the European Commission's Union Register of medicinal products (CC BY 4.0; the EU expiry date is calculated exactly as the Commission's register displays it). Listed patents and dates are as submitted to or published by the regulator and may not reflect litigation, invalidation, settlements, lapsed fees or later extensions. This is not legal advice or a freedom-to-operate opinion, and it does not say when a generic or biosimilar will launch.

What health systems spend on Paclitaxel

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$27.9m

70,163 prescriptions in 2025 · Paclitaxel, Abraxane, Paclitaxel Protein Bound Particles Albumin Bound

-26% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Paclitaxel works

All drug targets →

Tubulin inhibitor Inhibitor
Target: Tubulin
✓ In ChEMBL and the Guide to Pharmacology

Diseases it has been tested for in clinical trials, by furthest phase

AIDSPhase 3
Pancreatic cystsPhase 3
AdenocarcinomaPhase 3
Anal carcinomaPhase 3
Anal squamous cell carcinomaPhase 3
Biliary tract cancerPhase 3
Bladder carcinoma in situPhase 3
Bladder transitional cell carcinomaPhase 3
Bone metastasisPhase 3
CancerPhase 3

252 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL428647, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 2770, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

NICE appraisals of Paclitaxel

All NICE appraisals →

NICE, which decides whether the NHS in England should fund new medicines, has published 8 technology appraisals of Paclitaxel. 3 are current, and 2 of these recommend it for at least some patients. 5 older appraisals were replaced or withdrawn.

Appraisal	NICE recommendation	Published	Status
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer NICE TA389	Recommended Not recommended	27 Apr 2016	Current
Paclitaxel for the adjuvant treatment of early node-positive breast cancer NICE TA108	Not recommended	27 Sep 2006	Current
Guidance on the use of paclitaxel in the treatment of ovarian cancer NICE TA55	Recommended	22 Jan 2003 Updated 1 May 2005	Current

NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.

Patient leaflets for Paclitaxel

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 7 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
EU
European Union: Abraxane, Apexelsin (generic), Naveruclif (generic), Pazenir (generic)
EMA product information: package leaflet and summary of product characteristics in every EU language.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Paclitaxel

ATC code: L01CD01
ChEMBL: CHEMBL428647
DrugBank: DB01229
PubChem CID: 36314
CAS number: 33069-62-4
FDA UNII: 3PPC5TL76P
Wikidata: Q423762
Wikipedia: Paclitaxel

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting22252%
Not yet open379%
Active, closed16238%
By invitation20%

Trials by phase

Phase 315737%
Phase 215035%
Phase 1/25313%
Phase 1276%
Phase 2/3225%
Not applicable92%
Observational31%
Phase 420%

Clinical trials of Paclitaxel

423 trials

Study	Phase	Status	Lead sponsor	Registers
Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study) NCT07744698 · ClinicalTrials.gov ↗ · Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 4	Recruiting	Anhui Provincial Cancer Hospital	China
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC NCT07754812 · ClinicalTrials.gov ↗ · NSCLC (Non-small Cell Lung Cancer)	Phase 4	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors NCT02429687 · ClinicalTrials.gov ↗ · Ovarian Germ Cell Cancer, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Beihua Kong	China
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors NCT02429700 · ClinicalTrials.gov ↗ · Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Beihua Kong	China
Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women NCT03201861 · ClinicalTrials.gov ↗ · Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast	Phase 3	Recruiting	RenJi Hospital	China
Induction Chemotherapy Followed by Standard Therapy in Cervical Cancer With Aortic Lymph Node Spread NCT03534713 · ClinicalTrials.gov ↗ · Cervical Cancer TNM Staging Regional Lymph Nodes (N)	Phase 3	Recruiting	University Hospital, Toulouse	France
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients NCT03731442 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 3	Recruiting	Chinese Academy of Medical Sciences	China
Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT NCT04137653 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Shengjing Hospital	China
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) NCT04267848 · ClinicalTrials.gov ↗ · Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Norway, Mexico, Israel
Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC NCT04342910 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 NCT04400695 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	RemeGen Co., Ltd	China
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002) NCT04807673 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Tianjin Medical University Cancer Institute and Hospital	China
Niraparib vs Niraparib Plus Bevacizumab in Patients With Platinum/Taxane-based Chemotherapy in Advanced Ovarian Cancer NCT05009082 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer	Phase 3	Recruiting	AGO Study Group	Germany
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer NCT05188313 · ClinicalTrials.gov ↗ · Esophageal Cancer, Esophageal Adenocarcinoma	Phase 3	Recruiting	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Netherlands
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101) NCT05357846 · ClinicalTrials.gov ↗ · Squamous Cell Esophageal Carcinoma, Esophageal Cancer, Oesophageal Cancer	Phase 3	Recruiting	Sun Yat-sen University	China
A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. NCT05487391 · ClinicalTrials.gov ↗ · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd	China
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer NCT05624996 · ClinicalTrials.gov ↗ · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada, Mexico
Concurrent Chemoradiotherapy Combined With Adjuvant Chemotherapy Treated Advanced Cervical Cancer NCT05735145 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasms, Chemoradiotherapy, Adjuvant Chemotherapy	Phase 3	Recruiting	Fourth Affiliated Hospital of Guangxi Medical University	China
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer NCT05754853 · ClinicalTrials.gov ↗ · Advanced or Metastatic Urothelium Cancer	Phase 3	Recruiting	Shanghai Miracogen Inc	China
A Study of GLS-010 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer NCT05798819 · ClinicalTrials.gov ↗ · Persistent, Recurrent, or Metastatic Cervical Cancer	Phase 3	Recruiting	Guangzhou Gloria Biosciences Co., Ltd	China
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer NCT05929768 · Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8	Phase 3	Recruiting	SWOG Cancer Research Network	Mexico, Israel
Comparing Tunlametinib Capsules and Combination Chemotherapy in Advanced NRAS-mutant Melanoma NCT06008106 · ClinicalTrials.gov ↗ · Melanoma	Phase 3	Recruiting	Shanghai Kechow Pharma, Inc	China
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer NCT06058377 · ClinicalTrials.gov ↗ · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Israel
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer NCT06072781 · Low Grade Serous Ovarian Cancer	Phase 3	Recruiting	Verastem, Inc	Ireland, UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Canada, Japan, South Korea, Australia
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects NCT06079983 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05) NCT06103864 · Breast Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) NCT06312137 · Non Small Cell Lung Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176 · Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer NCT06340568 · Endometrial Cancer	Phase 3	Recruiting	BioNTech SE	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Brazil, South Korea, Taiwan, Singapore, Australia, Israel
A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma NCT06341335 · ClinicalTrials.gov ↗ · Gastric and Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Akeso	China
SHR-A1921 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06394492 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] NCT06422143 · Non-small Cell Lung Cancer, NSCLC	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Poland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
Phase III Study of Socazolimab as First-Line Treatment in Persistent, Recurrent, or Metastatic Cervical Cancer NCT06459687 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Recruiting	Lee's Pharmaceutical Limited	China
Utility of Adjusting Chemotherapy Dose & Dosing Schedule With the SALVage Weekly Dose-dense Regimen in Patients With Poor Prognostic OVARian Cancers Based on the Tumor Unfavorable Primary Chemosensitivity and Incomplete Debulking Surgery NCT06476184 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	ARCAGY/ GINECO GROUP	France, Italy, Netherlands, Japan
Study of Fruquintinib Plus Sintilimab for Treatment of Advanced Endometrial Cancer NCT06584032 · ClinicalTrials.gov ↗ · Advanced Endometrial Cancer	Phase 3	Recruiting	Hutchmed	China
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422 · Carcinoma, Non-Small-Cell Lung	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) NCT06644781 · Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	Daiichi Sankyo	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Norway, Japan, South Korea, Taiwan
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) NCT06692738 · Non-small Cell Lung Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases NCT06699212 · Recurrent Head and Neck Squamous Cell Carcinoma	Phase 3	Recruiting	Rakuten Medical, Inc	USA, China, Japan, Taiwan
A Phase III Study of SHR-A2102 Versus Investigator-selected Therapy in Advanced Urothelial Carcinoma NCT06738251 · ClinicalTrials.gov ↗ · Advanced Urothelial Carcinoma	Phase 3	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma NCT06743126 · Melanoma, Cutaneous Malignant, Mucosal Melanoma	Phase 3	Recruiting	Immatics US, Inc	UK, USA, Germany, France, Netherlands, Canada, Israel
Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer NCT06752811 · ClinicalTrials.gov ↗ · Pancreatic Cancer Metastatic	Phase 3	Recruiting	Shanghai Yizhong Pharmaceutical Co., Ltd	China
Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma NCT06793917 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 3	Recruiting	Fujian Cancer Hospital	China
A Study of SHR-A1811 in Subjects With Ovarian Cancer NCT06828354 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) NCT06841354 · Triple Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
HS-20089 for Injection in Patients With Platinum-Resistant Recurrent Epithelial Ovarian Cancer NCT06855069 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 3	Recruiting	Hansoh BioMedical R&D Company	China
Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated NCT06908993 · ClinicalTrials.gov ↗ · Advanced Non Small Cell Lung Cancer, MET Exon 14 Mutation	Phase 3	Recruiting	Intergroupe Francophone de Cancerologie Thoracique	France
Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer NCT06915025 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Ovarian Cancer, Fallopian Tube Cancer	Phase 3	Recruiting	Imunon	USA
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) NCT06952504 · Endometrial Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer NCT06954246 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd	China
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) NCT06966700 · Breast Neoplasms, Triple Negative Breast Neoplasms, HR Low-Positive/HER2-Negative Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer NCT06989112 · Endometrial Cancer	Phase 3	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Norway, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS) NCT06992882 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 3	Recruiting	Fudan University	China
INVIGORATE: A Study of QL1706 and Bevacizumab in Advanced First-Line Ovarian Clear Cell Carcinoma NCT07002346 · ClinicalTrials.gov ↗ · Ovarian Clear Cell Carcinoma	Phase 3	Recruiting	Tongji Hospital	China
Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) NCT07044336 · Endometrial Cancer, Malignant Solid Tumour	Phase 3	Recruiting	AstraZeneca	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) NCT07060807 · Breast Neoplasms	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer NCT07061977 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Adenosquamous Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Mexico, Israel
A Study of SKB264 Versus Investigator's Choice of Chemotherapy in Subjects With Unresectable Locally Advanced, Relapsed, or Metastatic HR+/HER2- Breast Cancer Who Have Previously Failed Endocrine Therapy NCT07071337 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 3	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer NCT07111832 · ClinicalTrials.gov ↗ · PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
Clinical Trial Comparing TQB2868 Injection Combined With Anlotinib Hydrochloride Capsules With Placebo Combined With Chemotherapy as First-line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) NCT07165951 · ClinicalTrials.gov ↗ · Metastatic Pancreatic Ductal Adenocarcinoma	Phase 3	Recruiting	Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd	China
A Phase III Clinical Study of Adebrelimab Combined With Concurrent Chemoradiotherapy Versus Placebo Combined With Concurrent Chemoradiotherapy for the Treatment of Locally Advanced Cervical Cancer NCT07168200 · ClinicalTrials.gov ↗ · Advanced Cervical Cancer	Phase 3	Recruiting	Shanghai Shengdi Pharmaceutical Co., Ltd	China
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer NCT07198074 · ClinicalTrials.gov ↗ · Advanced Endometrial Carcinoma, Recurrent Endometrial Carcinoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Mexico
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer NCT07213804 · Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms	Phase 3	Recruiting	Eli Lilly and Company	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) NCT07216703 · Cervical Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	Ireland, UK, USA, India, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer NCT07218809 · Epithelial Ovarian Cancer	Phase 3	Recruiting	AstraZeneca	Ireland, UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Switzerland, Czechia, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
JS107 vs Investigator's Choice as Second-line or Later Therapy for Advanced CLDN18.2-Positive Gastricor GEJ Adenocarcinoma. NCT07284134 · ClinicalTrials.gov ↗ · Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Shanghai Junshi Bioscience Co., Ltd	China
A Study to Investigate Mocertatug Rezetecan Compared With Standard of Care in Participants With Platinum-resistant Ovarian Cancer (BEHOLD-Ovarian01) NCT07286266 · Ovarian Neoplasms	Phase 3	Recruiting	GlaxoSmithKline	UK, Canada, Japan, South Korea, Australia
A Study to Investigate Mocertatug Rezetecan Compared With Chemotherapy in Participants With Endometrial Cancer After Platinum-based Chemotherapy and Immunotherapy (BEHOLD-Endometrial01) NCT07286331 · Neoplasms, Endometrial	Phase 3	Recruiting	GlaxoSmithKline	UK, USA, Canada, Brazil, Japan, South Korea, Australia, Israel
LM-108 in Combination With Toripalimab Versus Paclitaxel Injection for the Treatment of Subjects With CCR8-Positive Gastric and Gastroesophageal Junction Adenocarcinoma NCT07362186 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic GC and GCJ Adenocarcinoma	Phase 3	Recruiting	LaNova Medicines Limited	China
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer NCT07377643 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer	Phase 3	Recruiting	Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD	China
A Study of SHR-A2102 Versus Investigator's Choice of Chemotherapy in Patients With Platinum-based Chemotherapy and PD-(L)1 Inhibitor Treatment Failed Recurrent or Metastatic Cervical Cancer NCT07418749 · ClinicalTrials.gov ↗ · Recurrent Cervical Cancer, Metastatic Cervical Cancer	Phase 3	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031) NCT07419295 · Bladder Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Canada, Brazil, Japan, Australia, Israel
Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Advanced Head and Neck Cancer Who Cannot Receive Cisplatin NCT07441681 · ClinicalTrials.gov ↗ · Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma	Phase 3	Recruiting	NRG Oncology	Mexico
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy NCT07487896 · ClinicalTrials.gov ↗ · Advanced Esophageal Squamous Cell Carcinoma	Phase 3	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd	China
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment NCT07518147 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 3	Recruiting	Biokin (Shanghai) Biopharmaceutical Co., Ltd	China
Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab Compared to Investigator's Choice of Platinum-based Chemotherapy With or Without Bevacizumab as Second-line Treatment in Participants With Recurrent Platinum-sensitive Ovarian Cancer NCT07564141 · Platinum-Sensitive Ovarian Cancer, Ovarian Cancer	Phase 3	Recruiting	Genmab	USA, Japan
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China NCT07604766 · ClinicalTrials.gov ↗ · Platinum-resistant Ovarian Cancer	Phase 3	Recruiting	Genmab	China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+/HER2- Breast Cancer After Failure of Prior Endocrine Therapy(PANKU-Breast03) NCT07648914 · Breast Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study to Investigate Mocertatug Rezetecan With Bevacizumab Compared With Platinum Doublet With Bevacizumab in Participants With Platinum-sensitive Ovarian Cancer (BEHOLD-Ovarian02) NCT07684612 · ClinicalTrials.gov ↗ · Ovarian Neoplasms	Phase 3	Recruiting	GlaxoSmithKline	Canada, Japan, South Korea, Australia
A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05) NCT07743164 · ClinicalTrials.gov ↗ · Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	Phase 3	Recruiting	Merck Sharp & Dohme LLC	USA, Taiwan, Israel
A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants NCT07756645 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Recruiting	AbbVie	USA
HB0025-C-0301: A Study to Investigate HB0025 Combined With Chemotherapy as First-Line Treatment for Advanced or Recurrent MMR-proficient Endometrial Cancer NCT07902999 · ClinicalTrials.gov ↗ · First-line pMMR Endometrial Cancer	Phase 3	Recruiting	Shanghai Huaota Biopharmaceutical Co., Ltd	China
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer NCT04576143 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Neoadjuvant Chemotherapy	Phase 2/3	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
KN026 in Combination With Chemotherapy in HER2 Positive Gastric Cancer Subjects Who Have Failed First-line Therapy NCT05427383 · ClinicalTrials.gov ↗ · Stomach Cancer	Phase 2/3	Recruiting	Shanghai JMT-Bio Inc	China
BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer NCT06123884 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 2/3	Recruiting	Bio-Thera Solutions	China
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer NCT06161025 · Solid Cancer	Phase 2/3	Recruiting	Daiichi Sankyo	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial NCT06203600 · ClinicalTrials.gov ↗ · Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma	Phase 2/3	Recruiting	National Cancer Institute (NCI)	Mexico
DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy NCT06221748 · ClinicalTrials.gov ↗ · Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2/3	Recruiting	RemeGen Co., Ltd	China
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer (ROSETTA Lung-02) NCT06712316 · Non-small Cell Lung Cancer	Phase 2/3	Recruiting	BioNTech SE	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Turkey, Brazil, Japan, South Korea, Australia
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) NCT06926868 · Breast Neoplasms	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Sweden, Poland, Switzerland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion NCT07063745 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion	Phase 2/3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. NCT07365319 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer (Squamous or Non Squamous), Stage 4 NSCLC	Phase 2/3	Recruiting	Eikon Therapeutics	USA, Germany, Spain, Belgium, Poland, Austria, Brazil, Mexico, South Korea, Australia
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02) NCT07554456 · Esophageal Squamous Cell Carcinoma	Phase 2/3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
SCTB41 Combined With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer NCT07662395 · ClinicalTrials.gov ↗ · Double Blind	Phase 2/3	Recruiting	Sinocelltech Ltd	China
Chemoradiotherapy for Advanced Esophageal Cancer NCT02297217 · ClinicalTrials.gov ↗ · Esophageal Cancer	Phase 2	Recruiting	AHS Cancer Control Alberta	Canada
Folfox+Irinotecan+Chemort In Esophageal Cancer NCT04656041 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma, Esophagogastric Cancer	Phase 2	Recruiting	Massachusetts General Hospital	Israel
ATEMPT 2.0: Adjuvant T-DM1 vs TH NCT04893109 · ClinicalTrials.gov ↗ · Breast Cancer, HER2-positive Breast Cancer	Phase 2	Recruiting	Dana-Farber Cancer Institute	Israel
ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma NCT05014464 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Hunan Province Tumor Hospital	China
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy NCT05283226 · Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	NATCO Pharma Ltd	USA, India
ATATcH Alternating Treatment Plans for Advanced Cancer NCT05358548 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Lung Cancer	Phase 2	Recruiting	Rutgers, The State University of New Jersey	Israel
Novel Neoadjuvant and Adjuvant Strategy for Germline BRCA 1/2 Mutated Triple Negative Breast Cancer NCT05485766 · Triple Negative Breast Neoplasms, Triple Negative Breast Cancer, Breast Neoplasms	Phase 2	Recruiting	Okayama University	Japan
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial NCT05564377 · ClinicalTrials.gov ↗ · Advanced Malignant Solid Neoplasm, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8	Phase 2	Recruiting	National Cancer Institute (NCI)	Mexico, Israel, Egypt
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy NCT05582499 · ClinicalTrials.gov ↗ · Breast Neoplasm, Breast Cancer, Breast Tumors	Phase 2	Recruiting	Fudan University	China
First-line CBDCA/PTX/LEN/Pembrolizumab Combination for Previously Untreated Advanced or Recurrent Thymic Carcinomas (Artemis) NCT05832827 · ClinicalTrials.gov ↗ · Untreated Advanced or Recurrent Thymic Carcinomas	Phase 2	Recruiting	National Cancer Center, Japan	Japan
Trastuzumab Deruxtecan Versus Standard Neoadjuvant Treatment for HER2-positive Breast Cancer NCT05900206 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Recruiting	Karolinska University Hospital	Sweden
Nivolumab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma NCT05964101 · ClinicalTrials.gov ↗ · Neoplasms, Carcinoma, Squamous, Antineoplastic Agents	Phase 2	Recruiting	The First Affiliated Hospital of Guangzhou Medical University	China
Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy NCT05978648 · ClinicalTrials.gov ↗ · Breast Neoplasms	Phase 2	Recruiting	wang shusen	China
A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer NCT06038578 · Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Toray Industries, Inc	USA, Japan, South Korea
Paclitaxel and Ramucirumab +/- Zanidatamab in HER2 Postive Advanced Gastroesophageal Adenocarcinoma NCT06043427 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 2	Recruiting	Canadian Cancer Trials Group	Canada
Zimberelimab Combined With Albumin-bound Paclitaxel and Cisplatin in Neoadjuvant Treatment of LACC NCT06055738 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer	Phase 2	Recruiting	Tang-Du Hospital	China
Pembrolizumab and Chemotherapy Treatment or no Treatment Guided by the Level of TILs in Resected Early-stage TNBC NCT06078384 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 2	Recruiting	UNICANCER	France, Spain
Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma NCT06163729 · ClinicalTrials.gov ↗ · Gastroesophageal Junction Adenocarcinoma (Siewert II-III)	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer NCT06413992 · ClinicalTrials.gov ↗ · Endometrial Carcinoma, TP53 Mutation, Recurrent or Metastatic	Phase 2	Recruiting	Cancer Institute and Hospital, Chinese Academy of Medical Sciences	China
A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction Adenocarcinoma NCT06415669 · ClinicalTrials.gov ↗ · Gastric/Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	The First Affiliated Hospital of Xiamen University	China
A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer. NCT06434610 · ClinicalTrials.gov ↗ · Platinum-resistant Recurrent Ovarian Cancer	Phase 2	Recruiting	Shanghai Jiaolian Drug Research and Development Co., Ltd	China
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer NCT06437353 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 2	Recruiting	Anhui Provincial Cancer Hospital	China
Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer NCT06463028 · Endometrial Cancer	Phase 2	Recruiting	Faeth Therapeutics	USA
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors NCT06535607 · Sub-study 1 Cervical Cancer (Volrustomig Monotherapy), Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy), Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	Phase 2	Recruiting	AstraZeneca	UK, USA, China, Germany, Italy, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer NCT06561308 · ClinicalTrials.gov ↗ · Endometrioid Endometrial Cancer	Phase 2	Recruiting	Women's Hospital School Of Medicine Zhejiang University	China
Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCC NCT06601309 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Fujian Medical University Union Hospital	China
Benmelstobart Combined With Radiochemotherapy as Neoadjuvant Treatment Iin ESCC NCT06637163 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Shanghai Zhongshan Hospital	China
Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer NCT06656598 · ClinicalTrials.gov ↗ · Stage III NSCLC	Phase 2	Recruiting	Intergroupe Francophone de Cancerologie Thoracique	France
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer NCT06693336 · Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	ToLymph Inc	USA, Canada
A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) NCT06731907 · Non-small Cell Lung Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Turkey, Taiwan, Israel
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer NCT06735326 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer	Phase 2	Recruiting	Qilu Hospital of Shandong University	China
Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma NCT06764355 · ClinicalTrials.gov ↗ · ESCC, Total Neoadjuvant Treatment, Pathological Complete Response	Phase 2	Recruiting	National Taiwan University Hospital	Taiwan
A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)] NCT06783647 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03) NCT06797635 · Breast Neoplasms, Breast Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, South Korea, Taiwan
Evaluation of Clinical Efficacy and Safety of Specific Mode Electroacupuncture Stimulation for Paclitaxel Across BBB Delivery in Patients With Postoperative Recurrence of Malignant Glioma: A Single-arm Trial NCT06818331 · ClinicalTrials.gov ↗ · Glioma	Phase 2	Recruiting	The Third Affiliated hospital of Zhejiang Chinese Medical University	China
Testing Ivonescimab in Combination With Chemotherapy in Advanced or Metastatic Gastric/Gastroesophageal Adenocarcinoma NCT06846346 · ClinicalTrials.gov ↗ · Metastatic Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma	Phase 2	Recruiting	UNICANCER	France
Study of Cetuximab Plus/Minus Weekly Paclitaxel After Progression To First-Line Pembrolizumab Plus Platinum-5FU in Subjects With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. NCT06856213 · ClinicalTrials.gov ↗ · Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma	Phase 2	Recruiting	Grupo Español de Tratamiento de Tumores de Cabeza y Cuello	Spain
PALACE: Cemiplimab Trial According to ctDNA Levels NCT06917573 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic, Lung Diseases, Stage IV Non-small Cell Lung Cancer	Phase 2	Recruiting	Fundación GECP	Spain
Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer NCT06976944 · ClinicalTrials.gov ↗ · Recurrent Triple-Negative Breast Cancer	Phase 2	Recruiting	Yukinori Ozaki	Japan
Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer NCT07001618 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	France
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer NCT07007559 · Breast Cancer, Metastatic	Phase 2	Recruiting	ALX Oncology Inc	UK, USA, France, Spain, Italy, Canada, South Korea, Singapore
Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% NCT07020065 · ClinicalTrials.gov ↗ · Metastatic NSCLC - Non-Small Cell Lung Cancer	Phase 2	Recruiting	Swiss Cancer Institute	Switzerland
Personalized Timing of Interval Debulking Surgery in Advanced Ovarian Cancer NCT07023484 · ClinicalTrials.gov ↗ · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma	Phase 2	Recruiting	The University of Hong Kong	China
Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable Esophageal Squamous Cell Carcinoma NCT07039162 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC), Locally Advanced Unresectable Esophageal Cancer	Phase 2	Recruiting	Ming-Yu Lien	China, Taiwan
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer NCT07102381 · HER2-positive Breast Cancer, Breast Cancer	Phase 2	Recruiting	Jazz Pharmaceuticals	USA, Germany, Spain, Italy, Mexico
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC) NCT07108270 · ClinicalTrials.gov ↗ · Neoplasms, Endometrial	Phase 2	Recruiting	GlaxoSmithKline	China
Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma NCT07136519 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma (NPC)	Phase 2	Recruiting	Affiliated Hospital of Guangdong Medical University	China
Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) NCT07153445 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer	Phase 2	Recruiting	Fundación GECP	Spain
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013) NCT07221474 · Squamous Non-small Cell Lung Cancer	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, China, France, Spain, Italy, Poland, Turkey, South Korea, Taiwan, Australia
A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer NCT07229729 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
Perioperative Cadonilimab Combined With Neoadjuvant Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma (ESCC) NCT07263919 · ClinicalTrials.gov ↗ · Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Akeso	China
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT) NCT07283692 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 2	Recruiting	RenJi Hospital	China
Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC NCT07309952 · ClinicalTrials.gov ↗ · Locally Advanced Non-Small Cell Lung Cancer, Stage IIIb Non-small Cell Lung Cancer, Stage IIIC Non-Small Cell Lung Cancer	Phase 2	Recruiting	Yang Hong	China
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)] NCT07331155 · ClinicalTrials.gov ↗ · Advanced Solid Tumour	Phase 2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis NCT07384234 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	Phase 2	Recruiting	Ruijin Hospital	China
Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab Injection in the Second-Line Treatment for Immunotherapy-experienced Advanced Gastric Cancer NCT07392346 · Gastric Cancer Adenocarcinoma Metastatic	Phase 2	Recruiting	Dai, Guanghai	China
Neoadjuvant QL1706 in Patients With Hormone Receptor Positive, HER2-negative Breast Cancer NCT07396324 · ClinicalTrials.gov ↗ · HR-positive/HER2-negative Breast Cancer	Phase 2	Recruiting	RenJi Hospital	China
A Study of Alisertib and Paclitaxel in Patients With Small Cell Lung Cancer (SCLC) NCT07465757 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer ( SCLC )	Phase 2	Recruiting	Puma Biotechnology, Inc	USA, France, Spain
KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer NCT07481058 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Recruiting	Beijing Konruns Pharmaceutical Co., Ltd	China
A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680 · Solid Tumors	Phase 2	Recruiting	Bristol-Myers Squibb	Ireland, USA, China, Germany, France, Spain, Italy, Belgium, Norway, Canada, Japan, South Korea
Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma NCT07505186 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Neoadjuvant Therapy	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas NCT07546812 · HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma	Phase 2	Recruiting	Gilead Sciences	USA, France, Spain, South Korea, Australia
Induction Chemo-Immunotherapy + Radiotherapy vs Concurrent Chemoradiotherapy for Unresectable Locally Advanced Esophageal Squamous Cell Carcinoma NCT07559045 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma (ESCC)	Phase 2	Recruiting	Second Affiliated Hospital of Zunyi Medical University	China
Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study NCT07602907 · ClinicalTrials.gov ↗ · Advanced Breast Cancer, HER2-negative Breast Cancer	Phase 2	Recruiting	Zhejiang Cancer Hospital	China
Hypofractionated Definitive Chemoradiotherapy for Oesophageal Cancer NCT07632079 · ClinicalTrials.gov ↗ · Locally Advanced Esophageal or GE Junction Cancer	Phase 2	Recruiting	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Netherlands
Iparomlimab and Tuvonralimab Plus Paclitaxel and Platinum as Neoadjuvant Therapy for Locally Advanced Cervical Cancer NCT07646301 · ClinicalTrials.gov ↗ · Uterine Cervical Neoplasms, Locally Advanced	Phase 2	Recruiting	Sun Yat-sen University	China
A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) NCT07680764 · Locally Advanced Non-Small Cell Lung Cancer (NSCLC), Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 2	Recruiting	Bristol-Myers Squibb	UK, USA, China, Germany, France, Spain, Italy, Brazil, Australia
Neoadjuvant Cardonilizumab Combined With Neoadjuvant Chemoradiotherapy Can Resect Locally Advanced Esophageal Squamous Cell Carcinoma NCT07699185 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Recruiting	Tongji Hospital	China
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002) NCT07793942 · ClinicalTrials.gov ↗ · Malignant Neoplam, Advanced Solid Tumors	Phase 2	Recruiting	Merck Sharp & Dohme LLC	USA, Switzerland, Canada
Chemoradiotherapy in Elderly Patients With Oesophagus Cancer NCT02735057 · ClinicalTrials.gov ↗ · Oesophagus Cancer, Elderly Patients	Phase 1/2	Recruiting	Centre Hospitalier Universitaire de Besancon	France
KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) NCT04165070 · Carcinoma, Non-Small-Cell Lung	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Canada, South Korea, Taiwan, Israel
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) NCT04198766 · Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer	Phase 1/2	Recruiting	Inhibrx Biosciences, Inc	USA, South Korea, Taiwan, Singapore
Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer NCT04592211 · ClinicalTrials.gov ↗ · Gastric Cancer Stage IV	Phase 1/2	Recruiting	Yonsei University	South Korea
BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) NCT04752826 · Advanced Malignancies, Ovarian Cancer, T-cell Lymphoma	Phase 1/2	Recruiting	BioInvent International AB	UK, USA, Spain, Sweden, Denmark
A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma NCT04982276 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	Phase 1/2	Recruiting	Akeso	China
Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab NCT05319639 · ClinicalTrials.gov ↗ · Gastric Cancer Stage IV	Phase 1/2	Recruiting	Fujian Cancer Hospital	China
A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B) NCT05319730 · Esophageal Squamous Cell Carcinoma	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, Italy, Switzerland, Norway, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
Optimizing and Personalising Azacitidine Combination Therapy for Treating Solid Tumours QPOP and CURATE.AI NCT05381038 · ClinicalTrials.gov ↗ · Solid Tumor, Gastrointestinal Cancer, Breast Cancer	Phase 1/2	Recruiting	National University Hospital, Singapore	Singapore
Spevatamig (PT886) as Monotherapy or in Combination With Chemo and/or Targeted Therapy and/or ICI, for the Treatment of Patients With Advanced Gastrointestinal Cancers, Including Gastric, Gastroesophageal Junction, Pancreatic Ductal or Biliary Tract Carcinomas (the TWINPEAK Study) NCT05482893 · Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) NCT05652686 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer NCT05739981 · Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 1/2	Recruiting	Imunon	USA
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) NCT05824975 · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS)	Phase 1/2	Recruiting	GI Innovation, Inc	USA, South Korea
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. NCT05867420 · Advanced Solid Tumors	Phase 1/2	Recruiting	AskGene Pharma, Inc	USA, China
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis NCT06047379 · ClinicalTrials.gov ↗ · Diffuse Astrocytoma, IDH-Mutant, Glioblastoma, IDH-wildtype, Brain Metastases, Adult	Phase 1/2	Recruiting	Neonc Technologies, Inc	USA
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer NCT06202261 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer, Recurrent Breast Cancer, Advanced Malignancies	Phase 1/2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd	China
A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors NCT06208410 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	Risen (Suzhou) Pharma Tech Co., Ltd	China
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer NCT06385080 · Squamous Cell Carcinoma of Head and Neck	Phase 1/2	Recruiting	Janssen Research & Development, LLC	UK, USA, China, Germany, France, Spain, Poland, Japan, South Korea, Taiwan
Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) NCT06445972 · Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, France, Italy, Switzerland, Norway, Brazil, South Korea, Taiwan
A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors NCT06474455 · ClinicalTrials.gov ↗ · Advanced Solid Tumors	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
Induction IBI110 and Sintilimab with Chemotherapy in LA HNSCC NCT06494943 · ClinicalTrials.gov ↗ · Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma	Phase 1/2	Recruiting	Fudan University	China
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China, Australia
A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor NCT06758557 · ClinicalTrials.gov ↗ · Advanced NSCLC, Advanced Endometrial Cancer	Phase 1/2	Recruiting	Huabo Biopharm Co., Ltd	China
Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of LM-108 ± Penpulimab+Chemotherapy in Advanced Solid Tumors - Cohort C NCT06821503 · ClinicalTrials.gov ↗ · Advanced Pancreatic Cancer	Phase 1/2	Recruiting	Chia Tai Tianqing Pharmaceutical Group Co., Ltd	China
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer NCT06840002 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Recruiting	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003). NCT06843447 · Ovarian Cancer Recurrent	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	UK, USA, Spain, Switzerland, Canada, South Korea, Taiwan, Australia, Israel
Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer NCT06942234 · ClinicalTrials.gov ↗ · Inoperable Locally Advanced HER2-Negative Breast Cancer, Metastatic HER2-Negative Breast Cancer	Phase 1/2	Recruiting	Jiangsu Alphamab Biopharmaceuticals Co., Ltd	China
AK129 Combination Therapy for Advanced Solid Tumors NCT06943820 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer Stage IIIB/IV, Head and Neck Squamous Cell Carcinoma (HNSCC), Colorectal Adenocarcinoma	Phase 1/2	Recruiting	Akeso	China
A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors NCT06953323 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Wigen Biomedicine Technology (Shanghai) Co., Ltd	China
A Platform Study in Non-Small Cell Lung Cancer (NSCLC) NCT06996782 · Advanced or Metastatic Non-small Cell Lung Cancer	Phase 1/2	Recruiting	AstraZeneca	USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore
A Study of LBL-024 in Combination With Paclitaxel ± Bevacizumab for the Treatment of Platinum-resistant Ovarian Cancer NCT07042802 · ClinicalTrials.gov ↗ · Ovarian Cancer	Phase 1/2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
A Phase I/II Clinical Study of FH-006 for Injection in Patients With Malignant Solid Tumors NCT07136142 · ClinicalTrials.gov ↗ · Malignant Solid Tumor	Phase 1/2	Recruiting	Jiangsu HengRui Medicine Co., Ltd	China
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors NCT07229586 · ClinicalTrials.gov ↗ · Solid Tumor	Phase 1/2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors NCT07256782 · ClinicalTrials.gov ↗ · Advanced Solid Tumor	Phase 1/2	Recruiting	Qilu Pharmaceutical Co., Ltd	China
CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors NCT07335497 · Locally Advanced / Metastatic Solid Tumors	Phase 1/2	Recruiting	Crescent Biopharma, Inc	Ireland, UK, USA, France, Spain, Italy, South Korea, Australia
A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer NCT04516447 · ClinicalTrials.gov ↗ · Solid Tumor, Epithelial Ovarian Cancer, Fallopian Tube Cancer	Phase 1	Recruiting	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	USA, South Korea, Australia
A Study of NX-1607 in Adults With Advanced Malignancies NCT05107674 · Ovarian Cancer, Epithelial, Gastric Cancer, GastroEsophageal Junction (GEJ) Cancer	Phase 1	Recruiting	Nurix Therapeutics, Inc	UK, USA
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer NCT05142189 · Non-Small Cell Lung Cancer	Phase 1	Recruiting	BioNTech SE	UK, USA, Germany, Spain, Poland, Turkey, Australia
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer NCT05365581 · Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma	Phase 1	Recruiting	Astellas Pharma Global Development, Inc	USA, China, France, Spain, Italy, Japan, South Korea
First-in-human Study of OT-A201 in Patients With Selected Hematological Malignancies and Solid Tumors NCT05828459 · ClinicalTrials.gov ↗ · Hematological Malignancy, Solid Tumor	Phase 1	Recruiting	Onward Therapeutics	France
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors NCT05954312 · Advanced Solid Tumors	Phase 1	Recruiting	Vividion Therapeutics, Inc	USA, Spain, South Korea
A Study of TXN10128 in Subjects With Solid Tumors NCT05978492 · ClinicalTrials.gov ↗ · Locally Advanced (Unresectable) or Metastatic Solid Tumors	Phase 1	Recruiting	Txinno Bioscience Inc	South Korea
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors NCT06561685 · Metastatic Solid Tumor, Advanced Solid Tumor, Non-small Cell Lung Cancer	Phase 1	Recruiting	Eli Lilly and Company	USA, Germany, France, Spain, Japan, South Korea
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors NCT06586957 · ClinicalTrials.gov ↗ · Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult	Phase 1	Recruiting	NiKang Therapeutics, Inc	USA, South Korea
Zanzalintinib in Combination With Paclitaxel in Recurrent High Grade Uterine Cancer NCT06795009 · ClinicalTrials.gov ↗ · Uterine Cancer, Endometrial Cancer	Phase 1	Recruiting	Washington University School of Medicine	Mexico
A Study of PHST001 in Advanced Solid Tumors NCT06840886 · Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer	Phase 1	Recruiting	Pheast Therapeutics	USA
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer NCT06964009 · ClinicalTrials.gov ↗ · Ovarian Cancer, Ovarian Carcinoma, Recurrent Ovary Cancer	Phase 1	Recruiting	Elizabeth Stover, MD, PhD	Israel
A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC NCT06969612 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 1	Recruiting	Peking University Cancer Hospital & Institute	China
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma NCT07219212 · Squamous Cell Carcinoma of Head and Neck	Phase 1	Recruiting	Johnson & Johnson Enterprise Innovation Inc	USA, France, Spain, Japan
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer NCT07381829 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer	Phase 1	Recruiting	HC Biopharma Inc	China
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combinations in Advanced Solid Tumors NCT07477743 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer	Phase 1	Recruiting	HC Biopharma Inc	China
Antineoplastic Drugs in Elderly Patients NCT05467189 · ClinicalTrials.gov ↗ · Cancer	Observational	Recruiting	Shandong University	China
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer NCT06490159 · ClinicalTrials.gov ↗ · Gastric Cancer, Chemotherapy-induced Peripheral Neuropathy, Paclitaxel	Observational	Recruiting	City of Hope Medical Center	Japan
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery NCT04016389 · ClinicalTrials.gov ↗ · Cervical Cancer	Not applicable	Recruiting	University Health Network, Toronto	Canada
Paclitaxel (Albumin-bound) Combined With Oxaliplatin and S-1 Conversion Therapy for Gastric Adenocarcinoma NCT04047953 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma	Not applicable	Recruiting	Peking University Cancer Hospital & Institute	China
TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY NCT04481256 · Carcinoma, Squamous Cell, Oesophageal Cancer	Not applicable	Recruiting	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Netherlands
Phase III Study of Concurrent Radiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma (ESO-Shanghai 15) NCT04519905 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma, Chemoradiotherapy, Survival	Not applicable	Recruiting	Fudan University	China
Neoadjuvant Oral Paclitaxel Plus Subcutaneous Pertuzumab/Trastuzumab in Patients With HER2-positive Breast Cancer NCT07095023 · ClinicalTrials.gov ↗ · Breast Cancers	Not applicable	Recruiting	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	China
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer NCT07552402 · ClinicalTrials.gov ↗ · Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	Not applicable	Recruiting	Harbin Medical University	China
A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer NCT05990127 · ClinicalTrials.gov ↗ · Locally Advanced or Metastatic NSCLC	Phase 3	Not yet open	Akeso	China
Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer NCT07360132 · ClinicalTrials.gov ↗ · Squamous Non-small Cell Lung Cancer	Phase 3	Not yet open	Shanghai Huaota Biopharmaceutical Co., Ltd	China
A Study Comparing BL-M07D1 With Physician's Choice of Chemotherapy in Patients With HER2-Expressing Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer NCT07545460 · ClinicalTrials.gov ↗ · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
Paclitaxel, Ramucirumab and Tislelizumab Switch Maintenance in Advanced HER2-negative and PD-L1 TAP Score of 5 or More Advanced Gastroesophageal Adenocarcinoma NCT07763171 · ClinicalTrials.gov ↗ · Gastroesophageal Adenocarcinoma	Phase 3	Not yet open	Gruppo Oncologico del Nord-Ovest	Germany, Spain, Italy
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer NCT07821606 · ClinicalTrials.gov ↗ · Platinum-sensitive Recurrent Ovarian Cancer	Phase 3	Not yet open	Hansoh BioMedical R&D Company	China
HRS-4642 Combined With Antitumor Agents for the Treatment of Perioperative Pancreatic Cancer NCT07900789 · ClinicalTrials.gov ↗ · Systemic Treatment-naïve Pancreatic Cancer	Phase 3	Not yet open	Shanghai Hengrui Pharmaceutical Co., Ltd	China
A Phase II/III Clinical Study to Evaluate HLX07 in Combination With Serplulimab and Chemotherapy Versus Placebo in Combination With Serplulimab or Pembrolizumab and Chemotherapy as First-Line Treatment in Advanced Squamous Non-Small Cell Lung Cancer NCT07318883 · Squamous NSCLC	Phase 2/3	Not yet open	Shanghai Henlius Biotech	China
A Study Comparing BL-B01D1 in Combination With PD-1/VEGF Bispecific Antibody Versus Chemotherapy in Combination With PD-1/VEGF Bispecific Antibody in First-line Patients With Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer(PANKU-Lung05) NCT07739199 · ClinicalTrials.gov ↗ · Squamous Non-small-cell Lung Cancer	Phase 2/3	Not yet open	Sichuan Baili Pharmaceutical Co., Ltd	China
A Study to Learn the Safety and Efficacy of HLX37 in Combination With Chemotherapy for First-line Treatment in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer NCT07865910 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)	Phase 2/3	Not yet open	Shanghai Henlius Biotech	China
Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial) NCT04301375 · ClinicalTrials.gov ↗ · Mammary Cancer	Phase 2	Not yet open	David Garcia Cinca	Spain
Cyclin dEpendent Kinase in tRiple nEGatIVe brEast canceR - a "Window of Opportunity" Study NCT05067530 · ClinicalTrials.gov ↗ · Triple Negative Breast Neoplasms	Phase 2	Not yet open	Medical University of Gdansk	Poland
Adjuvant Therapeutic Cancer Vaccine (AST-201, pUMVC3-hIGFBP-2) in Patients With Advanced Ovarian Cancer NCT05794659 · Advanced Ovarian Cancer	Phase 2	Not yet open	Aston Sci. Inc	USA
Myeloprotection With Trilaciclib in Pan-cancer Population NCT06297811 · Non-Small Cell Lung Cancer, Breast Cancer, Endometrial Cancer	Phase 2	Not yet open	Sun Yat-sen University	China
Trial for Treatment of High Risk BC With Two Sequences of Neoadjuvant Chemotherapy With Pembrolizumab NCT06371807 · ClinicalTrials.gov ↗ · Early Breast Cancer, Triple Negative Breast Cancer	Phase 2	Not yet open	Fundacao Champalimaud	Portugal
Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC NCT06475755 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Anti Angiogenesis	Phase 2	Not yet open	Tang-Du Hospital	China
Efficacy of Organoid-Based Chemotherapy Drug Precision Screening to Guide Treatment for Thyroid Cancer NCT06713057 · ClinicalTrials.gov ↗ · Locally Advanced Thyroid Gland Carcinoma, Thyroid Cancer	Phase 2	Not yet open	West China Hospital	China
A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer NCT06745193 · ClinicalTrials.gov ↗ · Advanced Esophageal Carcinoma	Phase 2	Not yet open	Peking University	China
PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment NCT07028424 · ClinicalTrials.gov ↗ · PDAC - Pancreatic Ductal Adenocarcinoma	Phase 2	Not yet open	GERCOR - Multidisciplinary Oncology Cooperative Group	France
Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets NCT07234877 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Not yet open	European Organisation for Research and Treatment of Cancer - EORTC	Germany, France, Spain, Italy, Netherlands, Austria
Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) NCT07247786 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Respiratory Tract Neoplasm	Phase 2	Not yet open	Fundación GECP	Spain
Iparomlimab and Tuvonralimab (QL1706) Combined With Standard Chemotherapy or Combined With Intraperitoneal Perfusion Chemotherapy and Olaparib as Neoadjuvant Therapy for Advanced Ovarian Cancer NCT07407452 · ClinicalTrials.gov ↗ · Ovarian Cancers	Phase 2	Not yet open	Jiangsu Cancer Institute & Hospital	China
Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease NCT07420439 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic, Interstitial Lung Disease (ILD)	Phase 2	Not yet open	Intergroupe Francophone de Cancerologie Thoracique	France
Lurbinectedin Plus Paclitaxel Versus Paclitaxel in Patients With Previously Treated Small Cell Lung Cancer NCT07640932 · ClinicalTrials.gov ↗ · Carcinoma, Small Cell Lung	Phase 2	Not yet open	Yonsei University	South Korea
Iparomlimab and Tovorilimab (QL1706) Combined With Bevacizumab and Chemotherapy as Neoadjuvant Therapy for Advanced Ovarian Cancer NCT07663513 · ClinicalTrials.gov ↗ · Ovarian Cancers	Phase 2	Not yet open	Fudan University	China
An Umbrella-designed Prospective Multicenter Randomized Open-label Superiority Trial Evaluating Multi-biomarker-guided Precision Therapy for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma NCT07709533 · ClinicalTrials.gov ↗ · Valid MeSH Conditions	Phase 2	Not yet open	Sun Yat-sen University	China
Spatially Fractionated Radiotherapy With Tislelizumab and Chemotherapy for Bulky Stage III NSCLC: A Phase II Trial NCT07775040 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Not yet open	Sichuan Cancer Hospital and Research Institute	China
Trastuzumab Rezetecan and Carboplatin ± Bevacizumab Versus Investigator's Choice Chemotherapy in Patients With Platinum-sensitive Recurrent Ovarian Cancer NCT07776171 · ClinicalTrials.gov ↗ · Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC)	Phase 2	Not yet open	Sun Yat-sen University	China
Induction PD-1 Inhibitor and Chemotherapy Followed by Chemoradiotherapy in Unresectable or Inoperable HPV-negative LA-HNSCC NCT07776340 · ClinicalTrials.gov ↗ · HPV-unrelated Head and Neck Squamous Cell Carcinoma	Phase 2	Not yet open	Fudan University	China
Perioperative Adebrelimab for Locally Advanced Cervical Cancer NCT07811375 · ClinicalTrials.gov ↗ · Locally Advanced Cervical Cancer	Phase 2	Not yet open	Anhui Provincial Hospital	China
Quad Shot Radiotherapy Combined With Tislelizumab and Platinum-Based Chemotherapy Before Surgery for Stage II-III Non-Small Cell Lung Cancer NCT07845916 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Not yet open	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
An Open, Multicenter Phase II Clinical Trial of SHR-A2009 Combined With Other Anti-tumor Therapies for Perioperative Treatment of Resectable Non-small Cell Lung Cancer. NCT07863167 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Not yet open	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study to Assess The Safety and Tolerability of Pumitamig-Based Therapy Administered Before Surgery in Participants With Early-Stage Non-Small Cell Lung Cancer (ROSETTA Lung-220) NCT07871214 · Early-Stage Non-Small Cell Lung Cancer	Phase 2	Not yet open	Bristol-Myers Squibb	UK, USA, China, Germany, France, Spain, Italy, Poland, Canada, Japan, South Korea, Taiwan, Australia
A Study of Docetaxel for Injection (Albumin-bound) and SG001 in Combination With Cisplatin and Simultaneous Radiotherapy for Locally Advanced Unresectable Esophageal Squamous Carcinoma. NCT06136988 · ClinicalTrials.gov ↗ · Locally Advanced Unresectable Esophageal Squamous Carcinoma	Phase 1/2	Not yet open	CSPC ZhongQi Pharmaceutical Technology Co., Ltd	China
BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer NCT06620029 · Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm	Phase 1/2	Not yet open	BioMimetix JV, LLC	USA
HSK41959 With Standard Therapy in Solid Tumors With MTAP Deletion NCT07699757 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma (mPDAC), Advanced Solid Tumors	Phase 1	Not yet open	Haisco Pharmaceutical Group Co., Ltd	China
Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC NCT07093762 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Observational	Not yet open	Fuzhou General Hospital	China
Adjuvant Albumin-bound Paclitaxel Versus Taxanes in Breast Cancer: a Real-world Study NCT05287308 · ClinicalTrials.gov ↗ · Breast Cancer	Not applicable	Not yet open	Chinese Academy of Medical Sciences	China
Neoadjuvant Chemoradiotherapy Followed by Sequential Immunotherapy for Thoracic Esophageal Squamous Cell Carcinoma NCT06303583 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 1/2	By invitation	Qiu Guoqin	China
Carrelizumab Combined With Concurrent Radiotherapy and Chemotherapy for Unresectable Esophageal Squamous Cell Carcinoma NCT06048926 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Not applicable	By invitation	The First Affiliated Hospital with Nanjing Medical University	China
S0221 Adjuvant Doxorubicin, Cyclophosphamide, and Paclitaxel in Treating Patients With Breast Cancer NCT00070564 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	SWOG Cancer Research Network	Canada, Mexico, Israel
Doxorubicin Hydrochloride, Cyclophosphamide, and Paclitaxel With or Without Bevacizumab in Treating Patients With Lymph Node-Positive or High-Risk, Lymph Node-Negative Breast Cancer NCT00433511 · ClinicalTrials.gov ↗ · Breast Adenocarcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer NCT00565851 · ClinicalTrials.gov ↗ · Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Japan, South Korea
Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer NCT01081262 · ClinicalTrials.gov ↗ · Borderline Ovarian Mucinous Tumor, Ovarian Mucinous Cystadenocarcinoma, Recurrent Fallopian Tube Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer NCT01167712 · ClinicalTrials.gov ↗ · Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, South Korea, Israel
Induction Chemotherapy Plus Chemoradiation as First Line Treatment for Locally Advanced Cervical Cancer NCT01566240 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Active, closed	University College, London	India, Italy, Brazil, Mexico
The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma NCT01820858 · ClinicalTrials.gov ↗ · Endometrial Neoplasms	Phase 3	Active, closed	Ding Ma	China
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors NCT02375204 · Germ Cell Tumor, Teratoma, Choriocarcinoma	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Switzerland, Australia
Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02446600 · ClinicalTrials.gov ↗ · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Fallopian Tube Undifferentiated Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Japan, South Korea
Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) NCT02453282 · Non-Small-Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA, Germany, France, Spain, Italy, Netherlands, Belgium, Switzerland, Canada, Japan, South Korea, Taiwan, Australia
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer NCT02488967 · ClinicalTrials.gov ↗ · Breast Adenocarcinoma, Estrogen Receptor Negative, HER2/Neu Negative	Phase 3	Active, closed	NRG Oncology	Norway, Canada, Israel, Egypt
Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) NCT02542293 · Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Sweden, Denmark, Poland, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Singapore, Israel
Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) NCT03003962 · Non Small Cell Lung Carcinoma NSCLC	Phase 3	Active, closed	AstraZeneca	USA, China, Netherlands, Poland, Turkey, South Korea, Taiwan, Australia
A Randomized Controlled Trial of Neoadjuvant Weekly Paclitaxel Versus Weekly Paclitaxel Plus Weekly Carboplatin In Women With Large Operable or Locally Advanced, Triple Negative Breast Cancer NCT03168880 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Active, closed	Tata Memorial Hospital	India
A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients NCT03390686 · ClinicalTrials.gov ↗ · Lung Cancer, Non-small Cell Lung Cancer	Phase 3	Active, closed	Prestige Biopharma Limited	India, Poland, Turkey
Neoadjuvant Treatment of HER2 Positive Early High-risk and Locally Advanced Breast Cancer NCT03595592 · ClinicalTrials.gov ↗ · Invasive Breast Cancer	Phase 3	Active, closed	Fondazione Michelangelo	Germany, Spain, Italy, Austria
Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer (MK-3475-756/KEYNOTE-756) NCT03725059 · Breast Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Belgium, Poland, Portugal, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel, Egypt
Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients NCT03737643 · Advanced Ovarian Cancer	Phase 3	Active, closed	AstraZeneca	USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea
A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study NCT03768063 · Cancer	Phase 3	Active, closed	Hoffmann-La Roche	USA, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Czechia, Brazil, Mexico, Japan, South Korea, Australia, Israel
A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer NCT03800134 · Non-Small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer NCT03914612 · ClinicalTrials.gov ↗ · Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Japan, South Korea, Israel, Egypt
Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy NCT03977194 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer Metastatic	Phase 3	Active, closed	Intergroupe Francophone de Cancerologie Thoracique	France
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer NCT03981796 · Neoplasms	Phase 3	Active, closed	Tesaro, Inc	UK, USA, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Turkey, Canada, Israel
Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC NCT03997123 · Triple Negative Breast Neoplasms	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, France, Spain, Sweden, Poland, Czechia, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer NCT04025879 · Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Bristol-Myers Squibb	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Czechia, Canada, Brazil, Mexico, Japan, Taiwan, Australia
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer NCT04092283 · ClinicalTrials.gov ↗ · Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT04095364 · Low Grade Fallopian Tube Serous Adenocarcinoma, Ovarian Low Grade Serous Adenocarcinoma, Primary Peritoneal Low Grade Serous Adenocarcinoma	Phase 3	Active, closed	NRG Oncology	Ireland, Canada, Mexico, South Korea, Egypt
Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer NCT04158362 · ClinicalTrials.gov ↗ · Cancer Metastatic	Phase 3	Active, closed	UNICANCER	France
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer NCT04193059 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Fudan University	China
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer NCT04269200 · Endometrial Neoplasms	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, Spain, Belgium, Poland, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Australia, Israel
Carboplatin Intensified Chemotherapy for TRIple NEgative Breast Cancer(CITRINE) NCT04296175 · ClinicalTrials.gov ↗ · Triple-negative Breast Cancer	Phase 3	Active, closed	Fudan University	China
Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) NCT04379635 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 3	Active, closed	BeiGene	China
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea
Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer NCT04494425 · Advanced or Metastatic Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery NCT04498117 · Carcinoma, Ovarian Epithelial, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Active, closed	CanariaBio Inc	USA, India, Spain, Italy, Belgium, Czechia, Canada, Brazil, Mexico, South Korea, Taiwan
Evaluation of Sequencing of Anthracyclines and Taxanes for Locally Advanced HER2-negative Breast Cancer NCT04540692 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 3	Active, closed	Latin American Cooperative Oncology Group	Brazil
New Adjuvant Trial of Chemotherapy vs Chemo-immunotherapy NCT04564157 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer, Adjuvant Chemotherapy	Phase 3	Active, closed	Fundación GECP	Spain
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer NCT04579224 · ClinicalTrials.gov ↗ · Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053) NCT04634877 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea, Taiwan, Israel
Trastuzumab Deruxtecan for Subjects With HER2-Positive Gastric Cancer or Gastro-Esophageal Junction Adenocarcinoma After Progression on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04) NCT04704934 · Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma	Phase 3	Active, closed	Daiichi Sankyo	Ireland, UK, China, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Turkey, Brazil, Japan, South Korea, Taiwan, Singapore, Israel
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) NCT04895358 · Breast Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Sweden, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
A Study of AK104 Plus Platinum-containing Chemotherapy±Bevacizumab as First-line Treatment for Persistent, Recurrent, or Metastatic Cervical Cancer NCT04982237 · ClinicalTrials.gov ↗ · Cervical Cancer	Phase 3	Active, closed	Akeso	China
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C) NCT05112965 · ClinicalTrials.gov ↗ · Neoplasms	Phase 3	Active, closed	Hoffmann-La Roche	China
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer NCT05113251 · Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer	Phase 3	Active, closed	AstraZeneca	USA, India, China, Germany, Spain, Italy, Poland, Canada, Brazil, Japan, South Korea, Taiwan
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65). NCT05116189 · Ovarian Cancer, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Italy, Netherlands, Belgium, Denmark, Poland, Norway, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia, Israel
Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer NCT05116462 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 3	Active, closed	Innovent Biologics (Suzhou) Co. Ltd	China
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15) NCT05173987 · Endometrial Neoplasms	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Czechia, Norway, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia, Israel
Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma NCT05256225 · ClinicalTrials.gov ↗ · Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, South Korea
A Study to Evaluate the Efficacy and Safety of Giredestrant in Combination With Phesgo (Pertuzumab, Trastuzumab, and Hyaluronidase-zzxf) Versus Phesgo in Participants With Locally Advanced or Metastatic Breast Cancer (heredERA Breast Cancer) NCT05296798 · Locally Advanced or Metastatic Breast Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Portugal, Turkey, Brazil, Mexico, South Korea, Taiwan, Egypt
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02) NCT05374512 · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer NCT05382286 · Triple Negative Breast Cancer, PD-L1 Positive	Phase 3	Active, closed	Gilead Sciences	UK, USA, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer NCT05382299 · Triple Negative Breast Cancer, PD-L1 Negative	Phase 3	Active, closed	Gilead Sciences	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer NCT05502237 · Non-small Cell Lung Cancer	Phase 3	Active, closed	Gilead Sciences	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Israel
Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations NCT05687266 · NSCLC	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Sweden, Poland, Austria, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) NCT05722015 · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	USA, China, France, Spain, Poland, Turkey, Brazil, Japan, Taiwan
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy NCT05840211 · Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer	Phase 3	Active, closed	Gilead Sciences	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Austria, Czechia, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. NCT05984277 · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Czechia, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) NCT06018337 · Metastatic Breast Cancer	Phase 3	Active, closed	DualityBio Inc	UK, USA, China, Germany, France, Spain, Italy, Belgium, Poland, Turkey, Canada, South Korea, Australia, Israel
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer NCT06112379 · Breast Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Belgium, Poland, Switzerland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Singapore, Australia
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005) NCT06132958 · Endometrial Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Canada, Brazil, Mexico, Japan, South Korea, Singapore, Australia, Israel
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension NCT06212752 · ClinicalTrials.gov ↗ · Metastatic Non-small Cell Lung Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Japan
A Multicenter, Phase 3 Study of IBI343 Monotherapy Versus Treatment of Investigator's Choice in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, HER2-negative, Gastric or Gastroesophageal Junction Adenocarcinoma (G-HOPE-001) NCT06238843 · ClinicalTrials.gov ↗ · Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	Phase 3	Active, closed	Innovent Biologics (Suzhou) Co. Ltd	China, Japan
A Study of SKB264 Versus Investigator's Choice Chemotherapy in Patients With Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer NCT06279364 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 3	Active, closed	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01) NCT06304974 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 NCT06346392 · Gastric Cancer, Gastroesophageal Junction Cancer	Phase 3	Active, closed	AstraZeneca	UK, USA, India, China, Germany, France, Spain, Italy, Poland, Switzerland, Turkey, Canada, Brazil, Japan, South Korea, Taiwan
A Study to Evaluate Sacituzumab Tirumotecan (MK-2870) in Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-2870-015) NCT06356311 · Gastroesophageal Cancer	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Israel
Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Participants With Endometrial Cancer After Platinum-Based Chemotherapy and Immunotherapy (ASCENT-GYN-01/GOG-3104/ENGOT-en26) NCT06486441 · Endometrial Cancer	Phase 3	Active, closed	Gilead Sciences	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia, Israel
PM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer NCT06616532 · ClinicalTrials.gov ↗ · SCLC	Phase 3	Active, closed	Biotheus Inc	China
Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer NCT06619236 · ClinicalTrials.gov ↗ · Platinum-resistant Ovarian Cancer	Phase 3	Active, closed	Genmab	USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Austria, Czechia, Norway, Canada, Mexico, Japan, Australia, Israel
Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) NCT06726265 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	Phase 3	Active, closed	Immutep S.A.S	Ireland, UK, USA, India, Germany, Spain, Italy, Belgium, Poland, Austria, Portugal, Turkey, Canada, Brazil, Mexico, Australia
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Urothelial Carcinoma(PANKU-Bladder01) NCT06857175 · ClinicalTrials.gov ↗ · Urothelial Carcinoma	Phase 3	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer NCT01057069 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2/3	Active, closed	The Netherlands Cancer Institute	Netherlands
Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA NCT02135042 · ClinicalTrials.gov ↗ · EBV Infection, Stage II Nasopharyngeal Carcinoma AJCC v7, Stage III Nasopharyngeal Carcinoma AJCC v7	Phase 2/3	Active, closed	NRG Oncology	China, Canada, Taiwan, Singapore, Australia
Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients NCT02221999 · ClinicalTrials.gov ↗ · Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Ductal Breast Cancer	Phase 2/3	Active, closed	RenJi Hospital	China
Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer NCT02502266 · Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Japan, South Korea
Oral Paclitaxel Trial In Recurrent and Metastatic Breast Cancer As 1st Line Therapy NCT03315364 · ClinicalTrials.gov ↗ · Recurrent or Metastatic Breast Cancer	Phase 2/3	Active, closed	Daehwa Pharmaceutical Co., Ltd	China, South Korea
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002) NCT05506943 · Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer	Phase 2/3	Active, closed	Compass Therapeutics	USA, Mexico
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer NCT05800015 · Non-small Cell Lung Cancer	Phase 2/3	Active, closed	Regeneron Pharmaceuticals	USA, Turkey, Canada, Mexico, South Korea, Taiwan, Australia, Israel
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies NCT00781612 · Neoplasm Metastasis	Phase 2	Active, closed	Genentech, Inc	UK, USA, China, Germany, France, Spain, Italy, Belgium, Denmark, Poland, Switzerland, Czechia, Norway, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer NCT00977574 · ClinicalTrials.gov ↗ · Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico
Study to Compare the Efficacy and Safety of Olaparib When Given in Combination With Carboplatin and Paclitaxel, Compared With Carboplatin and Paclitaxel in Patients With Advanced Ovarian Cancer NCT01081951 · Ovarian Cancer	Phase 2	Active, closed	AstraZeneca	UK, USA, Germany, Spain, Italy, Netherlands, Belgium, Czechia, Canada, Japan, Australia
Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer NCT01142388 · ClinicalTrials.gov ↗ · Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Israel
Triple-B Study;Carboplatin-cyclophosphamide Versus Paclitaxel With or Without Atezolizumab as First-line Treatment in Advanced Triple Negative Breast Cancer NCT01898117 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	The Netherlands Cancer Institute	Netherlands
Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC NCT02259621 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer	Phase 2	Active, closed	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	Canada
SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer NCT02299999 · ClinicalTrials.gov ↗ · Metastatic Breast Cancer	Phase 2	Active, closed	UNICANCER	France
Improved Breast Cancer Therapy (I-BCT-1) in the Neoadjuvant and Metastatic Setting NCT02546232 · Breast Cancer	Phase 2	Active, closed	Oslo University Hospital	Norway
Neoadjuvant Response-guided Treatment of Luminal B-type Tumors and Luminal A-type Tumors With Node Metastases NCT02603679 · ClinicalTrials.gov ↗ · Early-Stage Breast Carcinoma, Estrogen Receptor Positive Tumor	Phase 2	Active, closed	Thomas Hatschek	Sweden
Multicentric Randomised Trial for Resectable Gastric Cancer NCT02931890 · ClinicalTrials.gov ↗ · Gastric Cancer	Phase 2	Active, closed	The Netherlands Cancer Institute	Netherlands
Concurrent Chemoradiotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma NCT03047265 · ClinicalTrials.gov ↗ · Nasopharyngeal Carcinoma	Phase 2	Active, closed	Sun Yat-sen University	China
Impact of Pegfilgrastim on Trastuzumab Anti-tumor Effect and ADCC in Operable HER2+ Breast Cancer Breast Cancer NCT03571633 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Operable Breast Cancer	Phase 2	Active, closed	Centre Leon Berard	France
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT03587311 · ClinicalTrials.gov ↗ · Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Canada
Adjuvant Palbociclib in Elderly Patients With Breast Cancer NCT03609047 · ClinicalTrials.gov ↗ · Breast Cancer Stage II, Breast Cancer Stage III	Phase 2	Active, closed	European Organisation for Research and Treatment of Cancer - EORTC	Germany, France, Spain, Italy, Belgium, Poland, Portugal
9-ING-41 in Patients With Advanced Cancers NCT03678883 · Cancer, Pancreatic Cancer, Sarcoma	Phase 2	Active, closed	Actuate Therapeutics Inc	USA, France, Spain, Netherlands, Belgium, Portugal, Canada
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP] NCT03747120 · ClinicalTrials.gov ↗ · HER2-positive Breast Cancer, Breast Cancer	Phase 2	Active, closed	University of Texas Southwestern Medical Center	Mexico
NADIM II: Neo-Adjuvant Immunotherapy NCT03838159 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	Fundación GECP	Spain
Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC NCT03965468 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer, Stage IV, Oligometastasis	Phase 2	Active, closed	ETOP IBCSG Partners Foundation	Spain, Italy, Netherlands, Switzerland
Combination Neoadjuvant Chemotherapy With or Without Apatinib for HER2 Negative Breast Cancer NCT03982485 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 2	Active, closed	RenJi Hospital	China
A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study NCT04215146 · Breast Cancer Metastatic	Phase 2	Active, closed	Oncolytics Biotech	USA
CompassHER2-pCR: Decreasing Chemotherapy for Breast Cancer Patients After Pre-surgery Chemo and Targeted Therapy NCT04266249 · Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer NCT04274426 · Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma	Phase 2	Active, closed	AGO Research GmbH	Germany
Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients NCT04293393 · ClinicalTrials.gov ↗ · Early Breast Cancer	Phase 2	Active, closed	Spanish Breast Cancer Research Group	Spain
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer NCT04310007 · ClinicalTrials.gov ↗ · Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
MARGetuximab Or Trastuzumab (MARGOT) NCT04425018 · ClinicalTrials.gov ↗ · Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer	Phase 2	Active, closed	Dana-Farber Cancer Institute	Israel
Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy NCT04554771 · ClinicalTrials.gov ↗ · Esophageal Adenocarcinoma, Oesophageal Adenocarcinoma, Resectable Carcinoma	Phase 2	Active, closed	Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)	Netherlands
A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC NCT04736823 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Akeso	China
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800 · Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma	Phase 2	Active, closed	National Cancer Institute (NCI)	Mexico, Egypt
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17) NCT04764227 · ClinicalTrials.gov ↗ · Esophagus Cancer, Esophageal Squamous Cell Carcinoma, Chemoradiotherapy	Phase 2	Active, closed	Fudan University	China
A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors NCT04931342 · Ovarian Cancer	Phase 2	Active, closed	Hoffmann-La Roche	UK, USA, Germany, France, Spain, Italy, Switzerland, Czechia, Turkey, Canada, South Korea, Australia
Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases NCT05012254 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer, Brain Metastases, Adult, Lung Cancer	Phase 2	Active, closed	Fundación GECP	Spain
A Clinical Study of SI-B001 in Combination With Paclitaxel/Docetaxel in the Treatment of Recurrent and Metastatic HNSCC NCT05054439 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	Sichuan Baili Pharmaceutical Co., Ltd	China
Selected Chemotherapy Combined Immunotherapy Treated High Risk Patient After NCRT in Resected Locally Advanced ESCC NCT05189730 · ClinicalTrials.gov ↗ · Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Sichuan Cancer Hospital and Research Institute	China
A Study of AK117/AK112 in Metastatic Triple-Negative Breast Cancer NCT05227664 · ClinicalTrials.gov ↗ · Metastatic Triple-negative Breast Cancer, Locally Advanced Triple-negative Breast Cancer	Phase 2	Active, closed	Akeso	China
AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC NCT05247684 · ClinicalTrials.gov ↗ · Resectable Non-small Cell Lung Cancer	Phase 2	Active, closed	Akeso	China
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer NCT05605535 · Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms	Phase 2	Active, closed	CanariaBio Inc	India
Study of Novel Treatment Combinations in Patients With Lung Cancer NCT05633667 · Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer	Phase 2	Active, closed	Gilead Sciences	UK, USA, Turkey, Brazil, South Korea, Taiwan, Israel
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors NCT05684276 · ClinicalTrials.gov ↗ · NSCLC, Pancoast Tumor	Phase 2	Active, closed	Fundación GECP	Spain
Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy NCT05781308 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer	Phase 2	Active, closed	Intergroupe Francophone de Cancerologie Thoracique	France
Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC) NCT05856695 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Active, closed	Intergroupe Francophone de Cancerologie Thoracique	France
A Study of PM8002 in Combination With Chemotherapy in Patients With SCLC NCT05879068 · ClinicalTrials.gov ↗ · SCLC	Phase 2	Active, closed	Biotheus Inc	China
A Three-arm Randomized Phase II Study of Dostarlimab Alone or With Bevacizumab Versus Nonplatinum Chemotherapy in Recurrent Gynecological Clear Cell Carcinoma: DOVE (APGOT-OV7/ ENGOT-ov80 Study) NCT06023862 · ClinicalTrials.gov ↗ · Ovarian Neoplasms, Endometrial Neoplasms, Uterine Cervical Neoplasms	Phase 2	Active, closed	Yonsei University	Japan, South Korea, Taiwan, Singapore, Australia
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery NCT06161441 · Resectable Non-small Cell Lung Cancer	Phase 2	Active, closed	Regeneron Pharmaceuticals	USA, Germany, France, Spain, Italy, Turkey, South Korea, Taiwan, Australia
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations NCT06194448 · Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, China, Spain, Turkey, South Korea, Taiwan, Israel
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC NCT06246110 · NSCLC	Phase 2	Active, closed	Eikon Therapeutics	USA
Study of SHR-8068 Combined With Adebrelimab and Platinum-containing Chemotherapy in the Treatment of Advanced Gastric and Esophageal Cancer NCT06247956 · ClinicalTrials.gov ↗ · Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma	Phase 2	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China
A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Japanese Participants With Primary Advanced or Recurrent Endometrial Cancer NCT06317311 · ClinicalTrials.gov ↗ · Carcinoma	Phase 2	Active, closed	GlaxoSmithKline	Japan
A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) NCT06378177 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	Lyvgen Biopharma Holdings Limited	China
Volrustomig Priming Regimens Exploratory Phase II Platform Study NCT06448754 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, China, France, Spain, Italy, Switzerland, Portugal, South Korea, Taiwan
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy NCT06449209 · Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer	Phase 2	Active, closed	BioNTech SE	UK, USA, Turkey, South Korea, Australia
Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy NCT06449222 · Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers	Phase 2	Active, closed	BioNTech SE	UK, USA, Turkey, Australia
Study to Evaluate Adverse Events and Change in Disease Activity When Intravenously (IV) Infused Livmoniplimab is Used in Combination With IV Infused Budigalimab in Adult Participants With Urothelial Carcinoma (UC) NCT06632951 · Urothelial Carcinoma	Phase 2	Active, closed	AbbVie	USA, France, Spain, Poland, Canada, Japan, South Korea, Israel
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01 NCT06727565 · Head and Neck Squamous Cell Carcinoma	Phase 2	Active, closed	Gilead Sciences	UK, USA, China, France, Spain, Italy, Taiwan, Australia
Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01) NCT06788912 · Lung Neoplasm Malignant	Phase 2	Active, closed	Merck Sharp & Dohme LLC	USA, Spain, Italy, Poland, Turkey
Efficacy of Tirellizumab Combined With Oral, Intravenous and Abdominal Chemotherapy in Peritoneal Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma NCT06914687 · ClinicalTrials.gov ↗ · Gastric Adenocarcinoma, Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma, Peritoneal Metastasis	Phase 2	Active, closed	Fudan University	China
JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC NCT06944470 · ClinicalTrials.gov ↗ · NSCLC	Phase 2	Active, closed	Shanghai Junshi Bioscience Co., Ltd	China
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) NCT06946797 · Non-Small Cell Lung Cancer	Phase 2	Active, closed	Bristol-Myers Squibb	USA, France, Italy, Poland, Brazil
JS207Combined With Chemotherapy in First-line Treatment of Advanced NSCLC NCT06969027 · ClinicalTrials.gov ↗ · Non-small Cell Lung Cancer	Phase 2	Active, closed	Shanghai Junshi Bioscience Co., Ltd	China
Study of IMNN-001 (Also Known as GEN-1) With NACT for Treatment of Ovarian Cancer (OVATION 2) NCT03393884 · Epithelial Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer	Phase 1/2	Active, closed	Imunon	USA, Canada
CFI-402257 in Combination With Paclitaxel in Patients With Advanced/Metastatic HER2-Negative Breast Cancer NCT03568422 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1/2	Active, closed	Canadian Cancer Trials Group	Canada
Paclitaxel + Carboplatin + Durvalumab With or Without Oleclumab for Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC NCT03616886 · ClinicalTrials.gov ↗ · Triple Negative Breast Cancer	Phase 1/2	Active, closed	Jules Bordet Institute	France, Belgium
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer NCT03742102 · Triple Negative Breast Neoplasms	Phase 1/2	Active, closed	AstraZeneca	UK, USA, Poland, Canada, South Korea, Taiwan
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor NCT04008797 · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular	Phase 1/2	Active, closed	Eisai Inc	USA, China, France, Spain, Italy, Denmark, Canada, Japan, South Korea, Taiwan
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors NCT04083599 · Malignant Solid Tumor, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)	Phase 1/2	Active, closed	Genmab	UK, USA, China, Germany, France, Spain, Italy, Denmark, South Korea, Taiwan, Israel
A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors NCT04495296 · ClinicalTrials.gov ↗ · Advanced Cancer	Phase 1/2	Active, closed	Transcenta Therapeutics (Hangzhou) Co., Ltd	China
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer NCT04538742 · Metastatic Breast Cancer	Phase 1/2	Active, closed	AstraZeneca	UK, USA, India, Germany, France, Spain, Italy, Poland, Turkey, Canada, Brazil, South Korea, Taiwan, Australia
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies NCT04644068 · Ovarian Cancer, Breast Cancer, Pancreatic Cancer	Phase 1/2	Active, closed	AstraZeneca	UK, USA, China, Spain, Italy, Poland, Czechia, Canada, Japan, South Korea, Australia
Study of TL117 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma NCT04843098 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Phase 1/2	Active, closed	Suzhou Junde Biotechnology Co., Ltd	China
Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer NCT04938583 · ClinicalTrials.gov ↗ · Ovarian Cancer by FIGO Stage, Ovarian Cancer Stage III, Ovarian Cancer Stage IV	Phase 1/2	Active, closed	CanariaBio Inc	South Korea
A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer NCT05275777 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer, Advanced Solid Tumor	Phase 1/2	Active, closed	National University Hospital, Singapore	Singapore
Onvansertib + Paclitaxel In TNBC NCT05383196 · ClinicalTrials.gov ↗ · Breast Cancer, Invasive Breast Cancer, Unresectable Breast Carcinoma	Phase 1/2	Active, closed	Antonio Giordano, MD	Israel
AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer NCT05904379 · ClinicalTrials.gov ↗ · Advanced Non-small-cell Lung Cancer	Phase 1/2	Active, closed	Akeso	China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies NCT03233139 · ClinicalTrials.gov ↗ · Advanced Malignancies	Phase 1	Active, closed	Regeneron Pharmaceuticals	Japan
A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors NCT03530397 · ClinicalTrials.gov ↗ · Selected Advanced Solid Tumors	Phase 1	Active, closed	MedImmune LLC	USA, France, Spain, Italy, Netherlands, Portugal, South Korea, Taiwan, Australia
DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC NCT03716180 · ClinicalTrials.gov ↗ · Breast Cancer	Phase 1	Active, closed	Dana-Farber Cancer Institute	Israel
A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer NCT04556773 · Metastatic Breast Cancer	Phase 1	Active, closed	AstraZeneca	USA, France, Belgium, Canada, Brazil, Mexico, South Korea, Taiwan, Australia
A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors NCT05117476 · Advanced Solid Tumor, NSCLC	Phase 1	Active, closed	Cullinan Therapeutics Inc	USA, Spain, Poland, Australia
Study of INCB123667 in Subjects With Advanced Solid Tumors NCT05238922 · Solid Tumors	Phase 1	Active, closed	Incyte Corporation	UK, USA, France, Italy, Netherlands, Switzerland, Japan
A Study of LOXO-783 in Patients With Breast Cancer/Other Solid Tumors NCT05307705 · Breast Cancer	Phase 1	Active, closed	Eli Lilly and Company	UK, USA, China, Germany, France, Spain, Belgium, Canada, Japan, South Korea, Singapore, Australia
Phase 1 Study of RP-6306 With Carboplatin and Paclitaxel in TP53 Ovarian and Uterine Cancer NCT06107868 · ClinicalTrials.gov ↗ · Recurrent Ovarian Cancer, Recurrent Uterine Cancer, Metastatic Cancer	Phase 1	Active, closed	University Health Network, Toronto	Canada
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer NCT06328738 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2 Positive Solid Tumors	Phase 1	Active, closed	Enliven Therapeutics	USA, France, Spain, Italy, Netherlands, Belgium, South Korea
Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). NCT06333951 · Thoracic Tumors, Non-small Cell Lung Cancer	Phase 1	Active, closed	Amgen	USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Austria, Turkey, Canada, Brazil, Japan, South Korea, Taiwan, Australia
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) NCT02194738 · ClinicalTrials.gov ↗ · Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8	Not applicable	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Israel

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Paclitaxel in the EU trials register (CTIS)

26 trials · 2 in Ireland

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Paclitaxel. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer 2025-524202-15-00 · Neoplasms	Phase 3	Ongoing	Genmab A/S	Ireland + 11 more
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2) 2025-522748-42-00 · Neoplasms	Phase 3	Ongoing	Incyte Corp	Ireland + 7 more
ABCSG 64 / neoGRACE: An open-label, two-arm, randomized phase II study of Sacituzumab Govitecan vs Standard of Care as neoadjuvant therapy for endocrine non-responsive ER+/HER2-negative early breast cancer 2025-520759-10-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Verein Zur Praevention Und Therapie Boesartiger Erkrankungen Austrian Breast And Colorectal Cancer Study Group	Austria
A Randomized, Open-Label, Multicenter, Phase 3 Study to Investigate Mocertatug Rezetecan with Bevacizumab Compared with Platinum Doublet with Bevacizumab in Participants with Platinum-Sensitive Ovarian Cancer 2025-523366-24-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Glaxosmithkline Research & Development Limited	Czechia, Poland, Austria + 9 more
DYNAMIC ” IDentifY the best therapeutic sequeNcing strAtegy in oncogene addICted NSCLC:” “A multi-arms prospective, randomized phase II study to evaluate the best sequential therapeutic strategis in patients with metastatic non-small cell lung cancer harboring targetable genomic driver alterations” 2026-525268-16-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Universita' Degli Studi Di Torino	Italy
EORTC-2456-LCG-BTG: A randomized phase II study evaluating upfront SRT to all brain metastases followed by ivonescimab plus chemotherapy versus upfront ivonescimab plus chemotherapy in patients with asymptomatic active brain metastases from NSCLC. 2025-522985-60-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	European Organisation For Research And Treatment Of Cancer	Slovenia, Spain, Germany + 5 more
A Pragmatic Phase II Study to Optimize Neoadjuvant Treatment and Surgical De-escalation in HR+/HER2− Early Breast Cancer Using Oncotype DX and Abemaciclib - VIOLET trial 2026-525457-37-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Istituto Di Ricerche Farmacologiche Mario Negri	Italy
A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients with Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309) 2025-524969-24-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Revolution Medicines Inc	Austria, Netherlands, Germany + 6 more
Addition of Platinum-based Chemotherapy to Tislelizumab in PD-L1high Metastatic Non-small Cell Lung Cancer with a High Tumor Burden (HighFive) [without IMPD-Q] 2026-525497-18-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	AIO-Studien gGmbH	Germany
IFEM – Pembrolizumab monotherapy versus pembrolizumab in combination with chemotherapy as first line therapy in females with advanced Non-small cell lung cancer (NSCLC) & PD-L1 expression ≥ 50% 2026-525387-18-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts	Germany
Pharmacokinetic study of pembrolizumab and its impact on immunity and the tumor microenvironment, which may explain the efficacy of post-immunotherapy chemotherapy - CPI 2026-526866-26-00 · Neoplasms	Phase 4	Authorised	Centre Antoine Lacassagne	France
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy 2025-523362-25-00 · Neoplasms	Phase 3	Authorised	Glaxosmithkline Research & Development Limited	Denmark, Netherlands, Italy + 9 more
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301) 2026-525617-31-00 · Neoplasms	Phase 3	Ongoing	Immuneering Corp	Spain, Czechia, Hungary + 6 more
Optimization of De-EscalatiON strategies in early breast cancer 2026-527524-27-00 · Neoplasms	Phase 2	Authorised	Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS	Italy
A phase II, open-label, randomized, multi-center study comparing the efficacy and safety of Sacituzumab govitecan versus investigator's choice in patients with cancer of unknown primary (CUP) who are relapsed after or refractory to platinum-based chemotherapy (SACICUP) 2025-523055-55-00 · Neoplasms	Phase 2	Authorised	Universitaetsklinikum Heidelberg AöR	Germany
DECREASE-IPC 2025-068 : De-Ecalating neoadjuvant Chemoimmunotherapy in early triple-negative BREASt cancer 2025-525040-18-00 · Neoplasms	Phase 2	Authorised	Institut Paoli Calmettes	France
COLOVERT – Conversion therapy in colorectal cancer with peritoneal metastases not amenable to upfront cytoreductive surgery and HIPEC: a phase II “pick-the-winner” open-label randomized trial 2026-526122-41-00 · Not possible to specify	Phase 2	Authorised	Uppsala University Hospital	Sweden
A Master Protocol of a Phase II, Open-label, Multicenter, Global Platform Study to Evaluate the Safety and Efficacy of Immunotherapy With or Without Other Anticancer Drugs in Participants with Unresectable Stage III Non-small Cell Lung Cancer Planning to Undergo Concurrent Chemoradiotherapy (AQUARIUS) 2025-523599-21-00 · Neoplasms	Phase 2	Authorised	AstraZeneca AB	Spain, Germany
REGENOVAR: A Phase I/II Study of Ubamatamab Plus Carboplatin, Paclitaxel, and Bevacizumab as Salvage Therapy in Ovarian Cancer with Poor Response to First-Line Chemotherapy. 2025-524232-20-00 · CTIS ↗ · Neoplasms	Phase 1	Authorised	Asso De Recherche Cancers Gynecologiques	France
A 2-part phase 1/2 open-label trial evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ODM-212 in combination with anti-cancer therapy in participants with advanced solid tumours 2025-524620-22-00 · CTIS ↗ · Neoplasms	Phase 1	Ongoing	Orion Corporation	Finland, Denmark, Spain + 1 more
TAILOR-PANC: Molecularly Tailored Therapy versus Standard Care in Advanced Pancreatic Cancer (DPCG-02) 2025-522431-34-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Region Hovedstaden	Denmark
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy 2024-519818-31-01 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Genmab A/S	Poland, Denmark, Finland + 8 more
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease 2025-521884-12-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	BioNTech SE	Czechia, Poland, Italy + 5 more
Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study 2025-521583-35-00 · CTIS ↗ · Neoplasms	Phase 2	Authorised	Universita' Vita-salute S. Raffaele	Italy
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36 2025-522084-15-00 · CTIS ↗ · Neoplasms	Phase 3	Authorised	IRCCS Istituto Nazionale Tumori Fondazione Pascale	Italy
A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (Bluestar-Endometrial01) 2024-518777-34-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	AstraZeneca AB	Italy, Netherlands, Lithuania + 12 more

Paclitaxel across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

7 single-substance products containing Paclitaxel on the HPRA medicines list.

Apacross 5 mg/ml powder for dispersion for infusionSeacross Pharma (Europe) Limited · PA22766/015/001 · Marketed
Paclitaxel 6 mg/ml concentrate for solution for infusionFresenius Kabi Deutschland GmbH · PA2059/050/001 · Marketed
Paclitaxel 6 mg/ml, Concentrate for Solution for InfusionAccord Healthcare Ireland Ltd. · PA2315/115/001 · Marketed
Abraxane 5 mg/ml powder for dispersion for infusionBristol-Myers Squibb Pharma EEIG · EU/1/07/428/001
Apexelsin 5 mg/ml powder for dispersion for infusion.Whiteoak Pharmaceutical B.V. · EU/1/24/1835/001

All 7 Irish products →

Supply shortages

AbraxaneEU (EMA) · Shortage resolved · first published 11 May 2023
PazenirEU (EMA) · Shortage resolved · first published 26 Jan 2023

EU shortages US shortages German shortages

Recent approvals

PaclitaxelFDA · 25 Jan 2002 · Generic (ANDA) · Teva Pharms

EMA approvals tracker FDA approvals tracker

Conditions studied with Paclitaxel

409 conditions

Breast Cancer32 Ovarian Cancer26 Non-small Cell Lung Cancer15 Esophageal Squamous Cell Carcinoma14 Non-Small Cell Lung Cancer13 Endometrial Cancer10 Breast Neoplasms9 Non Small Cell Lung Cancer9 Gastric Cancer9 Triple Negative Breast Cancer9 Advanced Solid Tumors9 Fallopian Tube Cancer9

All 409 conditions

Condition (as registered)	Trials
Breast Cancer	32
Ovarian Cancer	26
Non-small Cell Lung Cancer	15
Esophageal Squamous Cell Carcinoma	14
Non-Small Cell Lung Cancer	13
Endometrial Cancer	10
Breast Neoplasms	9
Non Small Cell Lung Cancer	9
Gastric Cancer	9
Triple Negative Breast Cancer	9
Advanced Solid Tumors	9
Fallopian Tube Cancer	9
Ovarian Neoplasms	8
Cervical Cancer	8
HER2-positive Breast Cancer	8
NSCLC	7
Advanced Solid Tumor	7
Endometrial Neoplasms	6
Triple Negative Breast Neoplasms	6
Head and Neck Squamous Cell Carcinoma	6
Metastatic Breast Cancer	6
Solid Tumor	6
Epithelial Ovarian Cancer	5
Carcinoma, Non-Small-Cell Lung	5
Gastroesophageal Junction Adenocarcinoma	5
Lung Cancer	5
Gastric Adenocarcinoma	5
Esophageal Cancer	5
Melanoma	4
Neoplasms	4
Peritoneal Cancer	4
Fallopian Tube Endometrioid Adenocarcinoma	4
Fallopian Tube Neoplasms	3
Advanced Malignancies	3
Metastatic Non-small Cell Lung Cancer	3
Cancer	3
Esophageal Adenocarcinoma	3
Primary Peritoneal Cancer	3
Head and Neck Cancer	3
Gastroesophageal Adenocarcinoma	3
HER2-negative Breast Cancer	3
Uterine Cervical Neoplasms	3
Chemoradiotherapy	3
Esophageal Squamous Cell Carcinoma (ESCC)	3
NSCLC (Advanced Non-small Cell Lung Cancer)	3
Non Small Cell Lung Cancer Metastatic	3
Fallopian Tube Mucinous Adenocarcinoma	3
Fallopian Tube Transitional Cell Carcinoma	3
Fallopian Tube Clear Cell Adenocarcinoma	3
Endometrial Clear Cell Adenocarcinoma	3
Anatomic Stage II Breast Cancer AJCC v8	3
Neoplasm Metastasis	2
Carcinoma, Ovarian Epithelial	2
Solid Tumors	2
Neoplasms, Endometrial	2
Squamous Cell Carcinoma of Head and Neck	2
Non Small Cell Lung Carcinoma NSCLC	2
Solid Cancer	2
Pancreatic Cancer	2
Locally Advanced Breast Cancer	2
Malignant Solid Tumor	2
Resectable Non-small Cell Lung Cancer	2
Platinum-resistant Ovarian Cancer	2
Carcinoma	2
Gastroesophageal Junction	2
Brain Metastases, Adult	2
Urothelial Carcinoma	2
Metastatic Solid Tumor	2
Squamous Non-small Cell Lung Cancer	2
Advanced Ovarian Cancer	2
Cholangiocarcinoma	2
Primary Peritoneal Carcinoma	2
Advanced Solid Tumor Cancer	2
Gastric Cancer Stage IV	2
Adjuvant Chemotherapy	2
SCLC	2
Advanced Solid Tumour	2
Endometrial Carcinoma	2
Ovarian Cancers	2
Triple-negative Breast Cancer	2
Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma	2
Tubular Breast Cancer	2
Mucinous Breast Cancer	2
Locally Advanced Cervical Cancer	2
Advanced Endometrial Cancer	2
Small Cell Lung Cancer Extensive Stage	2
Advanced Cancer	2
Oesophageal Cancer	2
Invasive Breast Cancer	2
Metastatic Esophageal Adenocarcinoma	2
Advanced Esophageal Adenocarcinoma	2
Advanced Gastric Adenocarcinoma	2
Early Breast Cancer	2
Breast Adenocarcinoma	2
Stage IIB Lung Cancer AJCC v8	2
Endometrial Dedifferentiated Carcinoma	2
Endometrial Endometrioid Adenocarcinoma	2
Stage III Lung Cancer AJCC v8	2
Anatomic Stage IIIA Breast Cancer AJCC v8	2
Anatomic Stage III Breast Cancer AJCC v8	2
Germ Cell Tumor	1
Teratoma	1
Choriocarcinoma	1
Germinoma	1
Locally Advanced / Metastatic Solid Tumors	1
Peritoneal Neoplasms	1
Low Grade Fallopian Tube Serous Adenocarcinoma	1
Ovarian Low Grade Serous Adenocarcinoma	1
Primary Peritoneal Low Grade Serous Adenocarcinoma	1
Stage II Fallopian Tube Cancer AJCC v8	1
Low Grade Serous Ovarian Cancer	1
Gastric Cancer, Adenocarcinoma	1
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Gastroesophageal Cancer	1
Advanced or Metastatic Non-Small-Cell Lung Cancer	1
Resectable Non-Small-Cell Lung Cancer	1
Malignant Solid Tumour	1
Gastroesophageal Junction Cancer	1
Ovarian Cancer Recurrent	1
Sub-study 1 Cervical Cancer (Volrustomig Monotherapy)	1
Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy)	1
Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
Sub-study 4 Esophageal Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)	1
T-cell Lymphoma	1
Lung Neoplasms	1
Prostate Cancer	1
PD-L1 Negative	1
Metastatic Triple Negative Breast Cancers	1
Locally Advanced or Metastatic Breast Cancer	1
HR Low-Positive/HER2-Negative Breast Neoplasms	1
Bladder Cancer	1
Locally Advanced Non-Small Cell Lung Cancer (NSCLC)	1
Metastatic Non-Small Cell Lung Cancer (NSCLC)	1
Extensive-stage Small-cell Lung Cancer	1
Small-cell Lung Cancer	1
Metastatic Non-small Cell Lung Cancer With MTAP Deletion	1
Advanced or Metastatic Breast Cancer	1
Early-Stage Non-Small Cell Lung Cancer	1
Breast Cancer, Metastatic	1
Locally Advanced or Unresectable Metastatic Breast Cancer	1
Stage IV Breast Cancer	1
PD-L1 Positive	1
Non-Small Cell Lung Cancer (NSCLC)	1
Colorectal Cancer (CRC)	1
Ovarian Cancer, Epithelial	1
GastroEsophageal Junction (GEJ) Cancer	1
Melanoma, Cutaneous Malignant	1
Mucosal Melanoma	1
Endometrial Cancer, Endometrial Neoplasm	1
Thoracic Tumors	1
Carcinoma, Hepatocellular	1
Liver Neoplasms	1
Selected Advanced Solid Tumors	1
Sarcoma	1
Renal Cancer	1
Recurrent Head and Neck Squamous Cell Carcinoma	1
Malignant Neoplam	1
Breast Cancer Metastatic	1
Solid Tumor, Adult	1
Metastatic Tumor	1
Non-Small-Cell Lung Carcinoma NSCLC	1
Ovarian Serous Adenocarcinoma	1
Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma	1
HER2-negative	1
Diffuse Astrocytoma, IDH-Mutant	1
Glioblastoma, IDH-wildtype	1
SMARCA4-Deficient Tumor	1
Gastric or Gastroesophageal Junction Adenocarcinoma	1
Pancreatic Ductal Adenocarcinoma	1
Biliary Tract Cancer (BTC)	1
Colorectal Cancer	1
Gastroesophageal Junction (GEJ) Adenocarcinoma	1
Pancreatic Adenocarcinoma	1
Small Cell Lung Cancer (SCLC)	1
Large Cell Neuroendocrine Cancer (LCNEC)	1
Neuroendocrine Prostate Cancer (NEPC)	1
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)	1
Esophageal Neoplasms	1
Soft Tissue Sarcoma (STS)	1
Platinum-resistant Ovarian Cancer (PROC)	1
HER2-positive Gastric Cancer	1
HER2 Positive Solid Tumors	1
HER2 Amplification	1
Carcinoma, Non-Small-Cell Lung Cancer (NSCLC)	1
HER2-positive Early Breast Cancer	1
Lung Neoplasm Malignant	1
Advanced or Metastatic Non-small Cell Lung Cancer	1
Platinum-Sensitive Ovarian Cancer	1
Non Small Cell Lung Cancer (Squamous or Non Squamous)	1
Stage 4 NSCLC	1
Biliary Tract Cancer	1
Gall Bladder Cancer	1
Ampullary Cancer	1
Small Cell Lung Cancer ( SCLC )	1
Ovarian Neoplasm Epithelial	1
Peritoneal Carcinoma	1
Non-small Cell Lung Cancer Stage IIIB/IV	1
Head and Neck Squamous Cell Carcinoma (HNSCC)	1
Colorectal Adenocarcinoma	1
Inoperable Locally Advanced HER2-Negative Breast Cancer	1
Metastatic HER2-Negative Breast Cancer	1
Neoadjuvant Chemotherapy	1
Locally Advanced Non-Small Cell Lung Cancer	1
Stage IIIb Non-small Cell Lung Cancer	1
Stage IIIC Non-Small Cell Lung Cancer	1
Platinum-resistant Recurrent Ovarian Cancer	1
Advanced Esophageal Squamous Cell Carcinoma	1
Metastatic Pancreatic Ductal Adenocarcinoma	1
Anti Angiogenesis	1
Neoadjuvant Therapy	1
Platinum-sensitive Recurrent Ovarian Cancer	1
Carcinoma, Squamous	1
Antineoplastic Agents	1
Advanced Cervical Cancer	1
Gastric and Gastroesophageal Junction Adenocarcinoma	1
TP53 Mutation	1
Recurrent or Metastatic	1
Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma	1
Locally Advanced	1
Pancreatic Cancer Metastatic	1
PD-L1-positive Locally Recurrent Unresectable or Metastatic Triple-negative Breast Cancer	1
Gastric Cancer Adenocarcinoma Metastatic	1
NSCLC (Non-small Cell Lung Cancer)	1
Persistent, Recurrent, or Metastatic Cervical Cancer	1
Recurrent Breast Cancer	1
Gastroesophageal Junction Adenocarcinoma (Siewert II-III)	1
Invasive Duct Carcinoma of Breast	1
Squamous Non-small-cell Lung Cancer	1
Breast Neoplasm	1
Breast Tumors	1
Triple-Negative Breast Cancer (TNBC)	1
Endometrioid Endometrial Cancer	1
Squamous NSCLC	1
Ovarian Germ Cell Cancer	1
Valid MeSH Conditions	1
Metastatic Triple-negative Breast Cancer	1
Locally Advanced Triple-negative Breast Cancer	1
Locally Advanced Thyroid Gland Carcinoma	1
Thyroid Cancer	1
Locally Advanced Unresectable Esophageal Squamous Carcinoma	1
HPV-unrelated Head and Neck Squamous Cell Carcinoma	1
Advanced Gastric Adenocarcinoma and Esophageal Squamous Cell Carcinoma	1
Systemic Treatment-naïve Pancreatic Cancer	1
Double Blind	1
Glioma	1
Recurrent or Metastatic Breast Cancer	1
Locally Advanced or Metastatic GC and GCJ Adenocarcinoma	1
Advanced or Metastatic Urothelium Cancer	1
Survival	1
Squamous Non-Small Cell Lung Cancer sqNSCLC	1
Extensive-stage Small Cell Lung Cancer (ES-SCLC)	1
Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma	1
Peritoneal Metastasis	1
Gastric Cancer or Gastroesophageal Junction Adenocarcinoma	1
Invasive Ductal Breast Cancer	1
Inflammatory Breast Cancer	1
Recurrent Cervical Cancer	1
Metastatic Cervical Cancer	1
Breast Cancers	1
Pancreatic Ductal Adenocarcinoma (mPDAC)	1
Nasopharyngeal Carcinoma	1
Locally Advanced Unresectable Esophageal Cancer	1
EBV Infection	1
Stage II Nasopharyngeal Carcinoma AJCC v7	1
Stage III Nasopharyngeal Carcinoma AJCC v7	1
Stage IVA Nasopharyngeal Carcinoma AJCC v7	1
Esophagus Cancer	1
Radiation Therapy	1
Stomach Cancer	1
Locally Advanced or Metastatic NSCLC	1
Advanced Gastric or Gastroesophageal Junction Adenocarcinoma	1
Ovarian Clear Cell Carcinoma	1
Advanced Pancreatic Cancer	1
HR-positive/HER2-negative Breast Cancer	1
Advanced NSCLC	1
Platinum Sensitive Ovarian Cancer (PSOC)	1
Advanced Urothelial Carcinoma	1
Ovarian Sex Cord Stromal Tumor	1
First-line pMMR Endometrial Cancer	1
Advanced Breast Cancer	1
Nasopharyngeal Carcinoma (NPC)	1
Squamous Cell Esophageal Carcinoma	1
Advanced Esophageal Carcinoma	1
Gastric/Gastroesophageal Junction Adenocarcinoma	1
Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	1
Advanced Non-small-cell Lung Cancer	1
Breast Cancer Stage II	1
Breast Cancer Stage III	1
Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma	1
Cervical Cancer TNM Staging Regional Lymph Nodes (N)	1
Advanced Non Small Cell Lung Cancer	1
MET Exon 14 Mutation	1
PDAC - Pancreatic Ductal Adenocarcinoma	1
Interstitial Lung Disease (ILD)	1
Oesophagus Cancer	1
Elderly Patients	1
Metastatic Gastric Adenocarcinoma	1
Hematological Malignancy	1
Cancer Metastatic	1
Operable Breast Cancer	1
Stage III NSCLC	1
Pancoast Tumor	1
Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma	1
Lung Diseases	1
Stage IV Non-small Cell Lung Cancer	1
Stage III Non-small Cell Lung Cancer	1
Stage IIIA Lung Cancer	1
Stage IIIB Lung Cancer	1
Mammary Cancer	1
Stage IV	1
Oligometastasis	1
Respiratory Tract Neoplasm	1
Carcinoma, Squamous Cell	1
Locally Advanced Esophageal or GE Junction Cancer	1
Oesophageal Adenocarcinoma	1
Resectable Carcinoma	1
Early-Stage Breast Carcinoma	1
Estrogen Receptor Positive Tumor	1
Metastatic NSCLC - Non-Small Cell Lung Cancer	1
Lung Non-Small Cell Carcinoma	1
Lung Non-Small Cell Squamous Carcinoma	1
Lung Non-Squamous Non-Small Cell Carcinoma	1
Stage II Lung Cancer AJCC v8	1
Estrogen Receptor Negative	1
HER2/Neu Negative	1
Progesterone Receptor Negative	1
Stage IB Lung Non-Small Cell Carcinoma AJCC v7	1
Stage II Lung Non-Small Cell Cancer AJCC v7	1
Stage IIA Lung Cancer AJCC v8	1
Ovarian Brenner Tumor	1
Fallopian Tube Serous Adenocarcinoma	1
Recurrent Ovarian Cancer	1
Recurrent Uterine Cancer	1
Metastatic Cancer	1
Fallopian Tube Undifferentiated Carcinoma	1
Ovarian Clear Cell Adenocarcinoma	1
Endometrial Mixed Cell Adenocarcinoma	1
Fallopian Tube High Grade Serous Adenocarcinoma	1
Ovarian Endometrioid Adenocarcinoma	1
Ovarian High Grade Serous Adenocarcinoma	1
Locally Advanced Lung Non-Small Cell Carcinoma	1
Anatomic Stage I Breast Cancer AJCC v8	1
Anatomic Stage IIIB Breast Cancer AJCC v8	1
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma	1
Locally Advanced Laryngeal Squamous Cell Carcinoma	1
Locally Advanced Oral Cavity Squamous Cell Carcinoma	1
Locally Advanced Oropharyngeal Squamous Cell Carcinoma	1
Borderline Ovarian Mucinous Tumor	1
Ovarian Mucinous Cystadenocarcinoma	1
Recurrent Fallopian Tube Carcinoma	1
Recurrent Ovarian Carcinoma	1
Metastatic Bladder Urothelial Carcinoma	1
Metastatic Urothelial Carcinoma	1
Refractory Bladder Urothelial Carcinoma	1
Refractory Urothelial Carcinoma	1
Ovarian Seromucinous Carcinoma	1
Platinum-Refractory Fallopian Tube Carcinoma	1
Platinum-Refractory Ovarian Carcinoma	1
Metastatic Lung Non-Squamous Non-Small Cell Carcinoma	1
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma	1
Stage IV Lung Cancer AJCC v8	1
Recurrent Lung Non-Small Cell Carcinoma	1
Stage IIIA Lung Cancer AJCC v8	1
Stage IIIB Lung Cancer AJCC v8	1
Anatomic Stage IIA Breast Cancer AJCC v8	1
Anatomic Stage IIB Breast Cancer AJCC v8	1
Locally Advanced Cervical Adenocarcinoma	1
Locally Advanced Cervical Adenosquamous Carcinoma	1
Locally Advanced Cervical Squamous Cell Carcinoma	1
Stage IIIA Cervical Cancer FIGO 2018	1
Clear Cell Adenocarcinoma	1
Uterine Cancer	1
Advanced Endometrial Carcinoma	1
Recurrent Endometrial Carcinoma	1
Advanced Gastroesophageal Junction Adenocarcinoma	1
Clinical Stage II Esophageal Adenocarcinoma AJCC v8	1
Endometrial Adenocarcinoma	1
Endometrial Adenosquamous Carcinoma	1
Endometrial Serous Adenocarcinoma	1
Advanced Malignant Solid Neoplasm	1
Anatomic Stage IV Breast Cancer AJCC v8	1
Locally Advanced Malignant Solid Neoplasm	1
Vulvar Cancer	1
Recurrent Triple-Negative Breast Cancer	1
Chemotherapy-induced Peripheral Neuropathy	1
Paclitaxel	1
Ramucirumab	1
Untreated Advanced or Recurrent Thymic Carcinomas	1
Locally Advanced (Unresectable) or Metastatic Solid Tumors	1
Ovarian Cancer by FIGO Stage	1
Ovarian Cancer Stage III	1
Ovarian Cancer Stage IV	1
Carcinoma, Small Cell Lung	1
ESCC	1
Total Neoadjuvant Treatment	1
Pathological Complete Response	1
Gastrointestinal Cancer	1
Unresectable Breast Carcinoma	1
Ovarian Carcinoma	1
Recurrent Ovary Cancer	1
Recurrent Platinum-Resistant Ovarian Carcinoma	1
HER2-Negative Breast Carcinoma	1
Hormone Receptor-Positive Breast Carcinoma	1
Esophagogastric Cancer	1
Stage II Breast Cancer	1
Stage III Breast Cancer	1
Metastatic Esophageal Squamous Cell Carcinoma	1
Metastatic Gastroesophageal Junction Adenocarcinoma	1
Recurrent Esophageal Adenocarcinoma	1

By country register

Register	Trials	Recruiting
Clinical trials in China	239	138
Clinical trials in USA	141	71
Clinical trials in Spain	115	48
Clinical trials in South Korea	112	49
Clinical trials in France	105	46
Clinical trials in Canada	93	35
Clinical trials in Italy	92	37
Clinical trials in Japan	90	41
Clinical trials in Germany	83	36
Clinical trials in UK	76	35
Clinical trials in Taiwan	76	34
Clinical trials in Poland	75	28
Clinical trials in Australia	72	33
Clinical trials in Mexico	69	22
Clinical trials in Israel	68	30
Clinical trials in Brazil	66	28
Clinical trials in Belgium	58	21
Clinical trials in Turkey	54	19
Clinical trials in Netherlands	48	20
Clinical trials in Czechia	32	13
Clinical trials in Austria	30	12
Clinical trials in Denmark	28	13
Clinical trials in India	28	9
Clinical trials in Singapore	27	13
Clinical trials in Sweden	24	14
Clinical trials in Switzerland	24	12
Clinical trials in Norway	23	12
Clinical trials in Portugal	21	5
Clinical trials in Ireland	20	10
Clinical trials in Egypt	8	1
EU register (CTIS)	26	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Paclitaxel trials

How many clinical trials are testing Paclitaxel?

423 current trials in our China, USA, Spain, South Korea, France, Canada, Italy, Japan, Germany, UK, Taiwan, Poland, Australia, Mexico, Israel, Brazil, Belgium, Turkey, Netherlands, Czechia, Austria, Denmark, India, Singapore, Sweden, Switzerland, Norway, Portugal, Ireland and Egypt registers name Paclitaxel as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.

Are Paclitaxel trials recruiting patients?

Yes. 222 of the 423 trials are recruiting: 138 with sites in China, 71 with sites in USA, 48 with sites in Spain, 49 with sites in South Korea, 46 with sites in France, 35 with sites in Canada, 37 with sites in Italy, 41 with sites in Japan, 36 with sites in Germany, 35 with sites in UK, 34 with sites in Taiwan, 28 with sites in Poland, 33 with sites in Australia, 22 with sites in Mexico, 30 with sites in Israel, 28 with sites in Brazil, 21 with sites in Belgium, 19 with sites in Turkey, 20 with sites in Netherlands, 13 with sites in Czechia, 12 with sites in Austria, 13 with sites in Denmark, 9 with sites in India, 13 with sites in Singapore, 14 with sites in Sweden, 12 with sites in Switzerland, 12 with sites in Norway, 5 with sites in Portugal, 10 with sites in Ireland and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Paclitaxel clinical trials?

Merck Sharp & Dohme LLC (30), AstraZeneca (28), National Cancer Institute (NCI) (22) and Akeso (10), among 204 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Paclitaxel clinical trials in Ireland?

Yes. 20 trials in our Ireland register (ClinicalTrials.gov), and 2 trials in the EU register (CTIS) list a site in Ireland. Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Paclitaxel licensed in Ireland?

Yes. The HPRA medicines list includes 7 single-substance products containing Paclitaxel, for example Apacross 5 mg/ml powder for dispersion for infusion (Seacross Pharma (Europe) Limited). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Paclitaxel shortage?

The registers we track list 2 entries for Paclitaxel: Abraxane (EU: shortage resolved); Pazenir (EU: shortage resolved). Shortages are product- and country-specific; check with a pharmacist.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Paclitaxel works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Paclitaxel works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Paclitaxel (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.